<table border="0" cellpadding="2" cellspacing="0"><tr><td>FN</td><td>Clarivate Analytics Web of Science</td></tr><tr><td>VR</td><td>1.0</td></tr><tr><td colspan="2"><hr/></td></tr><style type="text/css">
        table.FR_table_borders {-webkit-box-sizing: border-box; -moz-box-sizing: border-box;box-sizing: border-box; margin-top: 2px; outline: 1px solid #bababa; border-collapse: collapse;}
        table.FR_table_noborders .fr_address_row2:last-child {width: 100%}
        table.FR_table_borders th {vertical-align: middle; padding: 9px 10px 9px 9px;background: #f3f3f3; text-align: left;font-weight: bold;}
        table.FR_table_borders td {vertical-align: middle; padding: 5px;}
        table.FR_table_borders th, table.FR_table_borders td {border: 1px solid #CCCCCC; }
    </style><tr xmlns:date="http://exslt.org/dates-and-times" xmlns:str="http://exslt.org/strings" xmlns:exsl="http://exslt.org/common" xmlns:set="http://exslt.org/sets">
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017016372-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Coordination complex for photoinitiation for use in polymeric dental materials, such as adhesive systems, resin cements, composite resins, resin resins, flow resins, and infiltrating agent, comprises ligands derived from imino-pyridine unit</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">CARVALHO RAMOS SALLES DE; CARNEIRO SILVINO A; ROCHA M G; COELHO SINHORETI M A; BORTOLAZZO CORRER A</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C); UNIV FEDERAL RIO DE JANEIRO UFRJ (UYRI-Non-standard)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2019304295</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - A coordination complex for photoinitiation comprises ligands derived from imino-pyridine unit (I).<br>USE - A coordination complex for photoinitiation for use in polymeric dental materials, such as adhesive systems, resin cements, composite resins, resin resins, flow resins, infiltrating agents, pulp resins, resin modified ionomer cements, or photoactivation by light (all claimed).<br>ADVANTAGE - The coordination complex can absorb light in ranges the least harmful to the dentist and the patient.<br>DETAILED DESCRIPTION - A coordination complex for photoinitiation comprises ligands derived from imino-pyridine unit of formula (I).<br>R1=central metal ion.<br>An INDEPENDENT CLAIM is included for photoinitiation system comprising the coordination complex bisphenol A-glycidyl methacrylate (Bis-GMA) and triethylene glycol dimethacrylate (TEGDMA), in a ratio of 1:1 between monomers, in the presence of 0.2-5% additives.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">A96 (Medical, dental, veterinary, cosmetic.); A81 (Adhesives and binders - including chipboard.); ; G03 (Adhesives - excluding dispensers. Polymeric adhesives are also classified in Section A (C09H, J).); D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).); E12 (Organometallics - ie containing other than H, C, N, O, S, halogens, Si and P.); J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).); P84 (Other photographic (G03D-H).)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">A04-B09; A08-C09; A11-C02B; A12-V02B; G03-B02E; G06-D04; G06-F03B; G06-F03D; D08-A02; D08-B; E05-S; E05-T; E05-W; E10-A01; E10-B02A1; E10-E04G; E10-G02G1; E31-F03; E31-K07; J04-E</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G03F-007/029; B01J-031/18</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017016372-A2&nbsp;</td><td>19&nbsp;Mar&nbsp;2019</td><td>G03F-007/029&nbsp;</td><td>201933&nbsp;</td><td>Pages: 26&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017016372-A2&nbsp;</td><td>BR10016372&nbsp;</td><td>31&nbsp;Jul&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10016372&nbsp;</td><td>31&nbsp;Jul&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">M N; 129676-0-0-0K M; 191472-0-0-0K M; 208953-0-0-0K M; 134616-0-0-0K M</td>
</tr><tr>
<td valign="top"><B>MN </B></td><td>214070001 M N</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2019304295</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>





<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017015884-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Method for measuring non-linear effects applied to electro-optical component, involves characterizing distortion of amplitude, phase and frequency produced by complex dynamic electric and optical carriers on electro-optical component</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">CONFORTI E; SUTILI T; TAGLIETTI B; DE MELLO GALLEP C</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C); PADTEC SA (PADT-Non-standard)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201930429X</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The method involves synchronizing (C4) deviation of pulse phase modulation values, and evaluating (C5) phase distortion in which a light intensity signal is identified and processed by an electro-optical device. The electro-optical device is provided with modulators, keys and amplifiers in order to provide complete view of performance of the electro-optical device and to establish a correlation between distortion and non-linear effect with various properties of electromagnetic wave for characterization of distortion of amplitude, phase and frequency produced by complex dynamic electric and optical carriers present on a structure of the electro-optical component.<br>USE - Method for measuring non-linear effects applied to an electro-optical component.<br>ADVANTAGE - The method enables characterizing the distortion of the amplitude, the phase and the frequency produced by the complex dynamic electric and the optical carriers on the electro-optical component, thus optimizing operational parameters of the electro-optical component, and improving performance of the electro-optical component.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a flow diagram illustrating a method for measuring non-linear effects applied to an electro-optical component. '(Drawing includes non-English language text)'<br>Step for normalization of amplitude (C1)<br>Step for creating reference signal waveforms (C2)<br>Step for carrying out phase deviation analysis of sample signal (C3)<br>Step for synchronizing deviation of pulse phase modulation values (C4)<br>Step for evaluating phase distortion in which light intensity signal is identified and processed by electro-optical device (C5)<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">V07 (Fibre-optics and Light Control)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">V07-K01</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G02F-001/01; G02F-001/29</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017015884-A2&nbsp;</td><td>19&nbsp;Mar&nbsp;2019</td><td>G02F-001/01&nbsp;</td><td>201931&nbsp;</td><td>Pages: 35&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017015884-A2&nbsp;</td><td>BR10015884&nbsp;</td><td>25&nbsp;Jul&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10015884&nbsp;</td><td>25&nbsp;Jul&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201930429X</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017016603-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Use of neovestitol and vestitol combination for preparing a medicament for treating and preventing atherosclerosis</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">SILVA B B; ROSALEN P L; ALENCAR S M; PINTO ALVES MAYER M</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201930428R</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Use of neovestitol and vestitol combination is claimed for preparing a medicament for treating and preventing atherosclerosis.<br>USE - The combination is useful for preparing a medicament for treating and preventing atherosclerosis (claimed).<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B02 (Fused ring heterocyclics.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B06-A01; B14-F07; B14-S18</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61K-031/353; C07D-311/38; A61P-009/10</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017016603-A2&nbsp;</td><td>19&nbsp;Mar&nbsp;2019</td><td>A61K-031/353&nbsp;</td><td>201931&nbsp;</td><td>Pages: 24&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017016603-A2&nbsp;</td><td>BR10016603&nbsp;</td><td>02&nbsp;Aug&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10016603&nbsp;</td><td>02&nbsp;Aug&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">3428498-0-0-0K M; 110115-0-0-0K M</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201930428R</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">WO2019068152-A1</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Vector for expressing fluorescent proteins in Saccharomyces cerevisiae cells comprises sequences, where fluorescent proteins are expressed only in haploid, MATa and alpha cells</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">TEIXEIRA G S; FURLAN M; FARIAS A D S; PEREIRA G A G</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2019330758</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Vector comprises (SEQ ID NO: 1), not given in the specification. Sequences not defined here may be found at ftp://ftp.wipo.int/pub/published_pct_sequences/publication.<br>USE - Vector.<br>DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:<br>(1) an expression cassette including (SEQ ID NO: 26), which includes the promoter sequence of STE2 operably linked to the coding sequence of the EGFP gene and a CYC1 terminator sequence;<br>(2) a method for obtaining haploids of Saccharomyces cerevisiae was a high-throughput scale, which involves distinguishing haploid cells (MATa/MAT alpha ) from each other, between tetrad and diploid, transforming the diploid lineage (MATa/ alpha ) of interest with the vector pMF002, inducing the sporulation and tetrad formation of the line containing the vector, performing a procedure for the enzymatic lysis of tetrads, analyzing cells in flow cytometry using blue-laser (488nm) for excitation and filters for detecting green fluorescence (515-545nm) and orange (655-695nm), selecting green cell populations and orange; and<br>(3) performing haloides.<br>Sequences not defined here may be found at ftp://ftp.wipo.int/pub/published_pct_sequences/publication.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B04-E08; B04-E99; B04-F09C0E; D05-A02; D05-H12E; D05-H14A2; D05-H99</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">C12N-015/81; C12N-015/11; C12Q-001/04; C12N-015/64; C12N-001/19; C12R-001/865</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>WO2019068152-A1&nbsp;</td><td>11&nbsp;Apr&nbsp;2019</td><td>C12N-015/81&nbsp;</td><td>201930&nbsp;</td><td>Pages: 47&nbsp;</td><td>&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>WO2019068152-A1&nbsp;</td><td>WOBR000061&nbsp;</td><td>04&nbsp;Oct&nbsp;2018</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10021326&nbsp;</td><td>04&nbsp;Oct&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DS </B>
<BR>
</td><td valign="top">WO2019068152-A1:<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
               (National):
               AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
               (Regional):
               BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">93605-0-0-0N; 105730-0-0-0N</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2019330758</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">WO2019068153-A1</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Modulating gene expression in plants involves identifying and analysis of expression of genes induced by water stress in plants, confirming transcriptional profile in different organs in sugarcane plants in conditions of water deficit</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">TEIXEIRA M M; TSUNADA M S; ALESSIO V M; POLETTO I D O</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2019330757</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Modulating gene expression in plants involves identifying and analysis of expression of genes induced by water stress in plants, confirming the transcriptional profile in different organs of plants, preferably in sugarcane plants submitted to conditions of water deficit and control (continuous irrigation), isolating promoters via polymerase chain reaction (PCR) and cloning into plasmid vectors, such as PTZ57R/T or pGEMT-easy, in silico (computational) analysis of the presence of transcription factor binding motifs present in promoter sequences of (SEQ ID NOs: 1, 2 or 3), not given in the specification, cloning the promoter sequences of (SEQ ID NOs: 1, 2 or 3), not given in the specification, upstream of GUS gene into plasmid pQRE T1, and carrying out functional analysis of promoters of (SEQ ID NOs: 1, 2 or 3) by transient transformation of callus of plants, preferably of sugarcane. Sequences not defined here may be found at ftp://ftp.wipo.int/pub/published_pct_sequences/publication.<br>USE - Modulating gene expression in plants is used for the genetic transformation of cells, tissues or organs., and for the production of transgenic plants with abiotic stress tolerance characteristics or modification in desirable agronomic characteristics (all claimed).<br>DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a vectors, which comprises the DNA sequence of the modified pORE plasmid pORE Tl containing the DNA sequence defined by (SEQ ID NOs: 1, 2 or 3), not given in the specification operably linked to the coding sequence of the GUS gene, followed by terminator NOS, the vector includes in the T-DNA a modification in the geneticin/kanamycin resistance cassette defined by the insertion of the corn ubiquitin promoter operably linked to the coding region of the NPTII resistance gene, followed by the NOS terminator. Sequences not defined here may be found at ftp://ftp.wipo.int/pub/published_pct_sequences/publication.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">C06 (Biotechnology - including plant genetics and veterinary vaccines.); D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.); P13 (Plant culture, dairy products (A01G, H, J).)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">C04-A0800E; C04-E08; C04-E99; C04-F0800E; C14-U05; D05-H12E; D05-H16B; D05-H99</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">C12N-015/82; A01H-005/00; A01G-022/55; A01H-005/06</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>WO2019068153-A1&nbsp;</td><td>11&nbsp;Apr&nbsp;2019</td><td>C12N-015/82&nbsp;</td><td>201930&nbsp;</td><td>Pages: 42&nbsp;</td><td>&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>WO2019068153-A1&nbsp;</td><td>WOBR000062&nbsp;</td><td>04&nbsp;Oct&nbsp;2018</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10021330&nbsp;</td><td>04&nbsp;Oct&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DS </B>
<BR>
</td><td valign="top">WO2019068153-A1:<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
               (National):
               AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
               (Regional):
               BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">93605-0-0-0K U; 105730-0-0-0K U; 200757-0-0-0K P</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2019330757</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017018240-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Pharmaceutical composition used in the preparation of a medicament for the treating inflammation, comprises a fraction of phenanthroquinolizidine alkaloids and an acetophenone derivative extracted from Boehmeria caudate</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">PEREIRA DE PAIVA P; FOGLIO M A; TASCA GOIS RUIZ A L; NONATO F R; TEIXEIRA ZAFRED R R; TINTI S V; FIGUEIRA G M; DE CARVALHO J E</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201930425R</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - A pharmaceutical composition comprises a fraction of phenanthroquinolizidine alkaloids and an acetophenone derivative extracted from Boehmeria caudate; and carriers.<br>USE - The composition is used in the preparation of a medicament for the treating inflammation (claimed).<br>ADVANTAGE - The composition does not cause damage to normal cells.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); B02 (Fused ring heterocyclics.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B06-D18; B10-F02; B14-C03; B14-S18</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61K-031/4375; A61K-031/12; A61K-036/185; C07D-455/04; C07C-049/784; A61P-029/00</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017018240-A2&nbsp;</td><td>19&nbsp;Mar&nbsp;2019</td><td>A61K-031/4375&nbsp;</td><td>201930&nbsp;</td><td>Pages: 27&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017018240-A2&nbsp;</td><td>BR10018240&nbsp;</td><td>25&nbsp;Aug&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10018240&nbsp;</td><td>25&nbsp;Aug&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">839901-0-0-0K M; 839898-0-0-0K M; 227602-0-0-0K M</td>
</tr><tr>
<td valign="top"><B>RI</B></td><td valign="top">06263</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201930425R</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102016028723-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Performing bacterial cell transfection using hybrid polymer involves performing transformation by thermal shock of Escherichia coli DH5a using SBA-15/P particle as dopamine carrier, ecultive thawing of immortalized human keratinocytes</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">BARROS DE SOUSA E M; LANCELLOTTI M; DE HOLLANDA L M</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">COMISSAO NACIONAL ENERGIA NUCLEAR (NAEN-Non-standard); TECNOLOGIA &amp; PESQUISA INST ITP (TEPE-Non-standard); UNIV TIRADENTES-UNIT (UYTI-Non-standard); UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201920727N</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Performing bacterial cell transfection using hybrid polymer involves performing transformation by thermal shock of Escherichia coli DH5a using SBA-15/P (NIPAAM) 5x 2 particle as dopamine carrier pUC18/GFP + / Ampr, ecultive thawing of HaCaT cell lines (immortalized human keratinocytes, NIH/3T3 (Mus musculus fibroblast), A549 (alveolar adenocarcinoma of basal human lung cells), NG97 (astrocytoma grade III) at ambient temperature conditions; and c) transfection of the pIRES / GFP + plasmid using the nanoparticle SBA-15 / P (NIPAAM) 5x 2 comcharreador of exogenous gene material.<br>USE - Method for performing bacterial cell transfection using hybrid polymer.<br>ADVANTAGE - The method enables to perform bacterial cell transfection which saves time.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.); A85 (Electrical applications.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B04-F10A3E; B11-C12; D05-H14A1; A04-D04A2; A12-E10; A12-W11L; A12-W14</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">C12N-015/63; B82Y-099/00</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102016028723-A2&nbsp;</td><td>05&nbsp;Feb&nbsp;2019</td><td>C12N-015/63&nbsp;</td><td>201924&nbsp;</td><td>Pages: 27&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102016028723-A2&nbsp;</td><td>BR10028723&nbsp;</td><td>07&nbsp;Dec&nbsp;2016</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10028723&nbsp;</td><td>07&nbsp;Dec&nbsp;2016&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">200757-0-0-0K P</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201920727N</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017014836-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Pharmaceutical formulation used for topically treating wounds of animals infected with lymphadenitis, and inhibiting visible growth of Corynebacterium pseudotuberculosis, comprises phase A containing emollients, emulsifiers and waxes</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">TASIC L; DE MORAES PONTES J G; STANISIC D; DE BARROS C H N; DURAN CABALLERO N E; DIAS PORTELA R W; DE CARVALHO AZEVEDO V A</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C); UNIV FEDERAL DA BAHIA (UYBA-Non-standard); UNIV FEDERAL DE MINAS GERAIS-UFMG (UYMI-Non-standard)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2019140104</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Pharmaceutical formulation comprises phase A containing emollients, emulsifiers, waxes, butters, fatty alcohols, sterols and esters of sterols, fatty acids, salts and esters, oil ethers, humectants, solubilizers, solvents, neutralizers, gelling agent, stabilizing agent, controlling viscous agent, phospholipids, triglycerides and/or surfactants, and phase B containing 0.00001-50 wt.% 20% silver denanoparticles solution.<br>USE - Pharmaceutical formulation used for topically treating wounds of animals infected with lymphadenitis, and inhibiting visible growth of Corynebacterium pseudotuberculosis (all claimed).<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.); B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.); B06 (Inorganics - including fluorides for toothpastes etc.); ; D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B01-D02; B04-B01B; B04-B01C2; B04-B01C3; B05-A03B2; B05-B01P; B10-E04D; B10-G02; B14-A01; B14-N17B; B14-S18; D05-H08B</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61K-033/38; A61K-009/14; A61K-009/51; A61P-031/04; A61K-047/44</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017014836-A2&nbsp;</td><td>22&nbsp;Jan&nbsp;2019</td><td>A61K-033/38&nbsp;</td><td>201924&nbsp;</td><td>Pages: 23&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017014836-A2&nbsp;</td><td>BR10014836&nbsp;</td><td>10&nbsp;Jul&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10014836&nbsp;</td><td>10&nbsp;Jul&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">103243-0-0-0K M; 88527-0-0-0K M; 90458-0-0-0K M; 130767-0-0-0K M; 184612-0-0-0K M; 99130-0-0-0K M; 8349-1-0-0K M</td>
</tr><tr>
<td valign="top"><B>MN </B></td><td>213674901 K M</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">0148-S</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2019140104</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017004146-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Method for automatically repositioning of maxillary osseous segments during orthognathic surgery in three-dimensional virtual environment, involves calculating weights associated with cephalometric measures</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">DE MARTINO J M; MOLOGNI GONCALVES DOS SANT; PASSERI L A</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201920581V</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The method involves establishing automatic malocclusion correction skeletal model based on a maxilla model (e1). MSE, MSD, ISE and ISD points are marked in the maxilla model. Points of jaw model a displaced. A rotation axis is perpendicularly connected to line segments. Points of the maxilla model are rotated up to midpoint between the ISE and the ISD. Facial asymmetry is automatically corrected (e2). Jaw and chin discrepancies are automatically corrected (e3). Mean and standard deviations of a cephalometric pattern are measured (e4). Weights associated with cephalometric measures are calculated (e5).<br>USE - Method for automatically repositioning of maxillary osseous segments during orthognathic surgery in a three-dimensional (3D) virtual environment.<br>ADVANTAGE - The method enables automatically repositioning maxillary osseous segments so as to provide better convenience to surgeons during orthognathic surgery in 3D virtual environment.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a flow diagram illustrating a method for automatically repositioning of maxillary osseous segments.<br>Step for establishing automatic malocclusion correction skeletal model based on a maxilla model (e1)<br>Step for automatically correcting facial asymmetry (e2)<br>Step for automatically correcting jaw and chin discrepancies (e3)<br>Step for measuring mean and standard deviations of a cephalometric pattern (e4)<br>Step for calculating weights associated with cephalometric measures (e5)<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">P31 (Diagnosis, surgery (A61B).); P32 (Dentistry, bandages, veterinary, prosthesis (A61C, D, F).); T01 (Digital Computers)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">T01-J04A; T01-J06A</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61B-034/10; A61C-007/00</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017004146-A2&nbsp;</td><td>05&nbsp;Feb&nbsp;2019</td><td>A61B-034/10&nbsp;</td><td>201923&nbsp;</td><td>Pages: 42&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017004146-A2&nbsp;</td><td>BR10004146&nbsp;</td><td>02&nbsp;Mar&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10004146&nbsp;</td><td>02&nbsp;Mar&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201920581V</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017015258-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Inertial sensor calibration method, involves securing sensor in pan-tilt unit, moving OCT with sensor, performing data collection in inertial measurement unit, and carrying out STM matrix estimation in samples</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">KURKA P; ARMANDO DELGADO VARGAS J; DE MELLO SILVA P R; CORDOVA QUIROZ C H</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201915352W</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The method involves securing a sensor in a pan-tilt unit (PTU). A OCT is moved with the sensor. Data collection is performed in an inertial measurement unit (IMU). Synchronization of samples is performed in the PTU. The samples are converted from the OCT to the IMU. Calibration parameters are estimated by the sensor. Bias estimation and correction is carried out in the samples. STM matrix estimation is carried out in the samples. A cycle is repeated in times with constant velocity. Data is measured by the IMU during a movement process of the OCT.<br>USE - Inertial sensor calibration method.<br>ADVANTAGE - The method enables carrying out the STM matrix estimation in the samples, so that calibration accuracy of the inertial sensor can be improved and calibration time of the sensor can be reduced.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a flowchart illustrating an inertial sensor calibration method. '(Drawing includes non-English language text)'<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">S02 (Engineering Instrumentation)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">S02-G03; S02-G07A</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G01P-021/00</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017015258-A2&nbsp;</td><td>29&nbsp;Jan&nbsp;2019</td><td>G01P-021/00&nbsp;</td><td>201923&nbsp;</td><td>Pages: 23&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017015258-A2&nbsp;</td><td>BR10015258&nbsp;</td><td>17&nbsp;Jul&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10015258&nbsp;</td><td>17&nbsp;Jul&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201915352W</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017011378-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Producing lipid-polymeric nano-structured film used in immediate release of local anesthetics, and as pre-anesthetic for topical application particular in oral mucosa, involves preparing lipid component, selectively lipid carriers</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">DE MORAIS RIBEIRO L N; DE PAULA E; FRANZ-MONTAN M; DE CASTRO S R; RODRIGUES DA SILVA G; APARECIDA GUILHERME DAMASIO</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201909996H</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Producing lipid-polymeric nano-structured film involves preparing the lipid component, selectively the lipid carriers by homogenizing ultra-sonication, then preparing the bio-polymer component, and finally performing the preparation of films.<br>USE - Method for producing lipid-polymeric nano-structured film used for topical application of sustained release, preferably, application to mucous-membranes of sustained release, and topical application to mucous membrane of immediate release, used in immediate release of active component, preferably local anesthetics, in sustained release of active principles, preferably, local anesthetics, sustained release of lidocaine and prilocaine, also used as pre-anesthetic for topical application particular in oral mucosa (all claimed).<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">A96 (Medical, dental, veterinary, cosmetic.); B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.); B03 (Other heterocyclics.); B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">A05-H03; A05-H04; A12-V01; A12-W14; A12-W15; B04-C02D; B04-C02E3; B04-C02F; B04-C03B; B05-B02C; B06-D02; B07-B01; B07-D05; B10-B02F; B10-G02; B12-M10A; B12-M11Q; B12-M12B; B12-M15; B14-C07</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61K-031/167; A61K-047/14; A61K-009/107; A61P-023/02</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017011378-A2&nbsp;</td><td>18&nbsp;Dec&nbsp;2018</td><td>A61K-031/167&nbsp;</td><td>201923&nbsp;</td><td>Pages: 34&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017011378-A2&nbsp;</td><td>BR10011378&nbsp;</td><td>30&nbsp;May&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10011378&nbsp;</td><td>30&nbsp;May&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">101008-0-0-0K M; 148852-0-0-0K M; 90468-0-0-0K M; 99408-0-0-0K M; 104670-0-0-0K M; 91022-0-0-0K M; 100470-0-0-0K M; 87801-0-0-0K M; 89506-0-0-0K M; 106017-1-0-0K M; 86923-0-0-0K M; 110577-0-0-0K M; 103468-0-0-0K M; 104328-1-0-0K M; 107016-0-0-0K M; 104481-0-0-0K M; 104333-0-0-0K M; 133925-0-0-0; 444-0-0-0; 238-0-0-0</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">1117-S; 0648-S; 1694-S; 0975-S</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201909996H</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102013014877-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Synergistic composition used in fields of human and veterinary health, in pharmaceutical industries, control of infections in humans and other animals, is antimicrobial and contains bio-silver nano-particles and antibiotic produced</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">NAKAZATO G; KOBAYASHI R K T; ANDRADE G; DURAN CABALLERO N E; GASPARI P D M; DE OLIVEIRA A G; FERREIRA CARDOZO V</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNIV ESTADUAL LONDRINA (UYES-Non-standard); UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201910001Y</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Synergistic composition is an antimicrobial and contains bio-silver nano-particles and an antibiotic produced by Pseudomonas species.<br>USE - Synergistic composition can be used in the fields of human and veterinary health, preferably, in pharmaceutical industries, control of infections in humans and other animals, natural anti-microbial, packaging, veterinary products and dressings (claimed).<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B06 (Inorganics - including fluorides for toothpastes etc.); B02 (Fused ring heterocyclics.); C03 (Other organic compounds, inorganic compounds and multicomponent mixtures. Polymers and proteins.); ; D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B04-F09; B05-A03B2; B06-D14; B14-A01; B14-A02; B14-A04; B14-S09; B14-S18; C04-F09; C05-A03B2; C06-D14; C14-A01; C14-A02; C14-A04; C14-S09; C14-S18; D05-H08A</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61K-031/498; A61K-033/38; A61P-031/04</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102013014877-A2&nbsp;</td><td>18&nbsp;Dec&nbsp;2018</td><td>A61K-031/498&nbsp;</td><td>201923&nbsp;</td><td>Pages: 14&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102013014877-A2&nbsp;</td><td>BR10014877&nbsp;</td><td>14&nbsp;Jun&nbsp;2013</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10014877&nbsp;</td><td>14&nbsp;Jun&nbsp;2013&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">200757-0-0-0K M; 125607-0-0-0K M; 130767-0-0-0K M</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201910001Y</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017012756-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Producing esters of flavouring enzyme such as isoamyl acetate and eugenyl acetate immobilized in supercritical carbon dioxide involves performing process in batch mode or continuous mode in presence of Candida antarctica lipases</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">DOS SANTOS P; MARTINEZ J</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201913973C</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Producing esters of flavoring enzyme immobilized in supercritical carbon dioxide involves performing the process in batch mode or continuous mode in the presence of the Candida antarctica lipases immobilized in macroporous resin, where anionic-macroporous resin is poly (methyl methacrylate-co-divinylbenzene).<br>USE - Method for producing esters of flavoring enzyme such as isoamyl acetate and eugenyl acetate, where eugenyl acetate is used in pharmaceutical, cosmetic and dental industry with raw material and isoamyl acetate is used as co-solvent or fixative in aromatic essences (all claimed).<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.); D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.); D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).); A96 (Medical, dental, veterinary, cosmetic.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B10-G02; B11-A02C1; D05-A01A2; D05-A01B3; D05-C; D08-B12; A04-B10; A04-F06E5; A12-V00V; A12-V01; A12-V03C1; A12-V04; A12-W11L</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">C12P-007/62; C12N-011/08; C07C-069/12</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017012756-A2&nbsp;</td><td>15&nbsp;Jan&nbsp;2019</td><td>C12P-007/62&nbsp;</td><td>201919&nbsp;</td><td>Pages: 18&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017012756-A2&nbsp;</td><td>BR10012756&nbsp;</td><td>14&nbsp;Jun&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10012756&nbsp;</td><td>14&nbsp;Jun&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">1128-0-0-0K P; 24082-0-0-0K P; 2024-0-0-0K S; 7692-0-0-0K S; 4-0-0-0K S; 105703-0-0-0K U V; 7200-0-0-0</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">1058-P; 1046-S; 0651-S; 0840-S</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201913973C</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102014015963-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Producing probes for monitoring of protein Serine/Threonine phosphatase endogenous in cancer cells and monitoring alcohol dehydrogenases, involves maintaining mixture of sodium chloride, potassium carbonate, sodium iodide</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">NARSAIOLI A J; DE CARVALHO H F; DA COSTA SILVA GONCALVES C; OLIVEIRA BARBOSA G; BORGES PIMENTEL DE OLIVEIR</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201910001P</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Producing probes involves maintaining mixture of sodium chloride, potassium carbonate, sodium iodide and (3-bromopropoxi) (tert-butyl) dimethylsilane in dimethylformamide under stirring at 24-90 degrees C, adding water to stop reaction, extracting obtained mixture with dichloromethane, drying organic phases which is combined with magnesium sulfate, filtering with filter paper and concentrating in vacuum to rotary evaporator and purifying crude product obtained by chromatography flash with increasing proportions of ethyl acetate and hexane in ratio 8:2-1:1. The solid substrate (silicon) ether is treating with ion exchange resin 50-100 mesh alcohol metal and stirred at 25 degrees C for 1 hour. The residue is filtered and solvent is evaporated. The dibenzyl N,N-diisopropylphosphoramidite is added to probe and stirred at 25 degrees C for 3 hours. The reaction mixture to (-)78 degrees C and cloroperbenzoic acid is added. The temperature is cooled at 0 degrees C and kept under stirring for 1 hour.<br>USE - Method for producing probes used for monitoring of protein Serine/Threonine phosphatase endogenous in cancer cells and monitoring alcohol dehydrogenases (all claimed).<br>ADVANTAGE - The method enables to produce probes that is dynamic, and has better understanding of regulation.<br>DETAILED DESCRIPTION - The aqueous saturated solution of sodium sulfate is added and phases are separated. The aqueous phase is extracted with dichloromethane and organic phases is dried, filtered and concentrated under vacuum. The solution is Purified in by chromatography flash with increasing proportions of ethyl acetate and hexane in ratio 1:1-3:7. The product is treated in ethanol with inorganic support under vigorous stirring at 1 atmosphere at 25 degrees C for 4 hours. The reaction mixture is passed by column of celite and concentrated under vacuum to obtain probe.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.); B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); B02 (Fused ring heterocyclics.); S03 (Scientific Instrumentation)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">A12-M; A12-V03C2; B04-E05; B05-A01A; B05-A01B; B05-B01K; B05-B02C; B05-C04; B05-C05; B05-C07; B06-A01; B06-A02; B06-A03; B10-B02H; B10-D03; B10-G02; B10-H02F; B14-S18; S03-E09F</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">C07D-265/38; G01N-033/50</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102014015963-A2&nbsp;</td><td>18&nbsp;Dec&nbsp;2018</td><td>C07D-265/38&nbsp;</td><td>201919&nbsp;</td><td>Pages: 33&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102014015963-A2&nbsp;</td><td>BR10015963&nbsp;</td><td>27&nbsp;Jun&nbsp;2014</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10015963&nbsp;</td><td>27&nbsp;Jun&nbsp;2014&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">114-0-0-0K P Q; 23-0-0-0K P Q; 100007-0-0-0K P Q; 27-0-0-0K P Q; 107339-0-0-0K P Q; 107367-0-0-0K P Q; 31-0-0-0K P Q; 129500-0-0-0K P Q; 8182-0-0-0K P Q; 8312-0-0-0K P Q; 68-0-0-0K P Q; 84588-0-0-0K P Q; K P Q; 23810-0-0-0K P Q; 109903-0-0-0K P Q; 66693-0-0-0K P Q; 2659949-0-0-0K P Q; 85132-0-0-0K P Q</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">1706-P; 0278-P; 1680-P; 0345-P; 1722-P; 1744-P; 1135-P; 0480-P; 1654-P; 1391-P; 1594-P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201910001P</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">WO2019036777-A1; BR102017018129-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Obtaining silver biosynthetic nanoparticles involves producing spores in solid medium, standardizing spore solution for inoculation, producing biomass in liquid medium, filtering and obtaining biomass, and extracting reductase</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">FAVARO W J; FERREIRA L A B; GARCIA P V; DE JESUS M B; CABALLERO N E D; BANDEIRA FERREIRA L A; VIANNA GARCIA P</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2019197070</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Obtaining silver biosynthetic nanoparticles involves producing spores in solid medium, standardizing spore solution for inoculation, producing biomass in liquid medium, filtering and obtaining biomass, extracting reductase and quinone cofactors, and reducing silver (Ag+) and formation of nanoparticles, and washing nanoparticles by centrifugation.<br>USE - Method for obtaining silver biosynthetic nanoparticles used in the preparation of a human or veterinary medicament for treating cancer, preferably bladder cancer, more preferably non-muscle invasive urinary bladder cancer (CBNMI), where concentration is from 0.2-0.05 mg/ml (all claimed).<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B06 (Inorganics - including fluorides for toothpastes etc.); D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B05-A03B2; B11-A01C; B12-M11Q; B14-H01; D05-A04A; D05-C</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61K-033/38; A61P-035/00; C12P-003/00; C12R-001/77; C12P-001/02; C22B-011/00; B82B-003/00; B82Y-005/00</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>WO2019036777-A1&nbsp;</td><td>28&nbsp;Feb&nbsp;2019</td><td>C12P-003/00&nbsp;</td><td>201918&nbsp;</td><td>Pages: 28&nbsp;</td><td>&nbsp;</td>
</tr>
<tr>
<td>BR102017018129-A2&nbsp;</td><td>26&nbsp;Mar&nbsp;2019</td><td>C12P-003/00&nbsp;</td><td>201927&nbsp;</td><td>&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>WO2019036777-A1&nbsp;</td><td>WOBR000050&nbsp;</td><td>24&nbsp;Aug&nbsp;2018</td>
</tr>
<tr>
<td>BR102017018129-A2&nbsp;</td><td>BR10018129&nbsp;</td><td>24&nbsp;Aug&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10018129&nbsp;</td><td>24&nbsp;Aug&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DS </B>
<BR>
</td><td valign="top">WO2019036777-A1:<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
               (National):
               AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
               (Regional):
               BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA<BR>
</td>
</tr><tr>
<td valign="top"><B>CP </B>
<BR>
</td><td valign="top">
<table cellspacing="5" cellpadding="1" border="0">
<tr valign="top">
<td valign="top">WO2019036777-A1</td><td nowrap="true">BR200605681-A</td><td>UNICAMP UNIV ESTADUAL CAMPINAS (UNIC-Non-standard);  ORG MOGIANA EDUCACAO &amp; CULTURA SIMPLES (MOGI-Non-standard)</td><td>CABALLERO N E D;  ALVES O L;  ESPOSITO E;  DE SOUZA G I D M;  GASPARI P D M</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CR </B>
<BR>
</td><td valign="top">
<table cellspacing="5" cellpadding="0" border="0">
<tr valign="top">
<td>WO2019036777-A1</td><td>FERREIRA, L. A. B.: "Citotoxicidade, endocitose e processamento celular de nanoparticulas biossinteticas de prata em macrofagos peritoneais", DISSERTACAO- UNICAMP, 2015, Campinas, pages 1 - 70, XP055578340,relevantClaims[1 to 12],relevantPassages[. Abstract last pargraph from pagef 3; item 3.1, to page 16; item 4.1, to pages 26 e 27; Figure 1 ; Table 2; Annex 3, to page 69.]</td>
</tr>
<tr valign="top">
<td>&nbsp;</td><td>SALAHELDIN, T. A. ET AL.: "Evaluation of the cytotoxic behavior of fungai extracellular synthesized Ag nanoparticles using confocal laser scanning microscope", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES., vol. 17, no. 3, March 2016 (2016-03-01), pages 329, XP055578345, DOI: 10.3390/ijms17030329,relevantClaims[1 to 12],relevantPassages[. Abstract; itens 2.2, 2.3, 3.2, 3.3.]</td>
</tr>
<tr valign="top">
<td>&nbsp;</td><td>FAVARO, W. J.: "Nanoparticula Biossintetica de Prata: Perspectiva Terapeutica para o Cancer de Bexiga Urinaria Nao-Musculo Invasivo", 14 CONGRESSO DA SOCIEDADE LATINO AMERICAN A DE BIOMATERIAIS , ORGAOS ARTIFICIAIS E ENGENHARIA DE TECIDOS- SLABO, 21 August 2017 (2017-08-21), XP055578367,relevantClaims[11, 12|1 to 10],relevantPassages[. The whole document.]</td>
</tr>
<tr valign="top">
<td>&nbsp;</td><td>PICOLI, S. U. ET AL.: "Silver nanoparticles/silver chloride (Ag/AgCI) synthesized from Fusarium oxysporum acting against Klebsiella pneumouniae carbapenemase (KPC) and extended spectrum b eta-lactamase (ESBL", FRONTIERS IN NANOSCIENCE AND NANOTECHNOLOGY, vol. 2, no. 2, January 2016 (2016-01-01), pages 107 - 110, XP055578373, ISSN: 2397-6527, DOI: 10.15761/FNN.1000117,relevantClaims[1 to 10|11, 12],relevantPassages[. Abstract, section "Partly Experimental" e "Results and discussions".]</td>
</tr>
<tr valign="top">
<td>&nbsp;</td><td>CASTIGLIONI, S. ET AL.: "Silver nanoparticles-induced cytotoxicity requires ERK activation in human bladder carcinoma cells", TOXICOLOGY LETTERS, vol. 237, no. 3, 17 September 2015 (2015-09-17), pages 237 - 243, XP055578380, ISSN: 0378-4274, DOI: 10.1016/j.toxlet.2015.06.1707,relevantClaims[11, 12|1 to 10],relevantPassages[. Abstrac, section "Discussion".]</td>
</tr>
<tr valign="top">
<td>&nbsp;</td><td>LONGHI, C. ET AL.: "Combination of fluconazole with silver nanoparticles produced by Fusarium oxysporum improves antifungal effect against planktonic cells and biofilm of drug-resista nt Candida albicans", MEDICAL MYCOLOGY, vol. 54, no. 4, May 2015 (2015-05-01) - 19 June 2015 (2015-06-19), pages 428 - 432, XP055578391, DOI: 10.1093/mmy/myv036,relevantClaims[1 to 10|11, 12],relevantPassages[. Abstract, section "Materials e Methods".]</td>
</tr>
<tr valign="top">
<td>&nbsp;</td><td>GAIKWAD, S.C. ET AL.: "Screening of different Fusarium species to select potential species for the synthesis of silver nanoparticles", JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY, vol. 24, no. 12, December 2013 (2013-12-01), pages 1974 - 1982, DOI: 10.5935/0103-5053.20130247,relevantClaims[1 to 10|11, 12],relevantPassages[. Abstract, section "Experimental" and "Results and discussions".]</td>
</tr>
<tr valign="top">
<td>&nbsp;</td><td>DURAN, N. ET AL.: "Mechanistic aspects of biosyntheis of silver nanoparticles by several Fusarium oxysporum strains", JOURNAL OF NANOBIOTECHNOLOG Y, vol. 3, 13 July 2005 (2005-07-13), pages 1 - 7, XP021008674, ISSN: 1477-3155, DOI: 10.1186/1477-3155-3-8,relevantClaims[1 to 10|11, 12],relevantPassages[. Abstract, section "Methods", Figure 1.]</td>
</tr>
<tr valign="top">
<td>&nbsp;</td><td>ALMEIDA, E. S. ET AL.: "Characterization of silver nanoparticles produced by biosynthesis mediated by Fusarium oxysporum und er different processing conditions", BIOPROCESS AND BIOSYSTEMS ENGINEERING, vol. 40, no. 9, 24 May 2017 (2017-05-24), pages 1291 - 1303, XP036301650, ISSN: 1615-7591, DOI: 10.1007/s00449-017-1788-9,relevantClaims[1 to 10|11, 12],relevantPassages[. Abstract, sections "Materias and Methods", Table 2, Figure 8.]</td>
</tr>
<tr valign="top">
<td>&nbsp;</td><td>ISHIDA, K. ET AL.: "Silver nanoparticle production by the fungus Fusarium oxysporum: nanoparticle characterisation and analysis of antifungal activity against pathogenic yeasts", MEMORIAS DO INSTITUTO OSWALDO CRUZ, vol. 109, no. 2, April 2014 (2014-04-01), pages 220 - 228, XP055578401, DOI: 10.1590/0074-0276130269,relevantClaims[1 to 10|11, 12],relevantPassages[. Abstract, sections "Materials and Methods" and "Results", Table 1.]</td>
</tr>
<tr valign="top">
<td>&nbsp;</td><td>BIRLA, S. S. ET AL.: "Rapid synthesis of silver nanoparticles from Fusarium oxysporum by optimizing physicocultural conditions", THE SCIENTIFIC WORLD JOURNAL, vol. 2013, 30 August 2013 (2013-08-30), pages 1 - 12, XP055578403, ISSN: 1537-744X, DOI: 10.1155/2013/796018,relevantClaims[1 to 10|11, 12],relevantPassages[Abstract, sections "Experimental", Figures.]</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">130767-0-0-0K P; 823-0-0-0K S</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">1760-S</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2019197070</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017011377-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Composition used in anesthetic formulation for anticyciceptive application, comprises pharmaceutically acceptable excipients, (2E, 8E)-N-isobutyldeca-2,8-dien-6-inamide derivative and composition does not cause adverse systemic effects</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">CEZAR PASTRE J; GONCALVES ALONSO I; RODRIGUES R A F; YAMANE L T; DE PAULA E; VILA NOVA RODRIGUES M; DE FREITAS BLANCO V; BRAGA LEITE M F M; FERNANDO TONETO NOVAES L</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201909996J</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Composition comprises pharmaceutically acceptable excipients, (2E, 8E)-N-isobutyldeca-2,8-dien-6-inamide derivative having molecular weight 219.32 and represented by (I).<br>USE - Composition used in anesthetic formulation for anticyciceptive application (claimed).<br>ADVANTAGE - The composition does not cause adverse systemic effects, pain or discomfort.<br>DETAILED DESCRIPTION - Composition comprises pharmaceutically acceptable excipients, (2E, 8E)-N-isobutyldeca-2,8-dien-6-inamide having molecular weight 219.32 and represented by formula (I).. An INDEPENDENT CLAIM is included for a anesthetic formulation comprises composition with (2E, 8E)-2-isobutyldeca-2,8-dien-6-inamide as active principle.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.); B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.); A96 (Medical, dental, veterinary, cosmetic.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B04-C02A1; B04-C02A2; B04-C02B2; B04-C02E3; B04-C03A; B04-C03C; B07-A02A; B10-A09B; B10-C04D; B10-D03; B10-E04C; B12-M12B; B14-C07; B14-C08; B14-S18; A10-E09; A12-V01</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">C07C-233/09; A61K-031/16; A61K-036/28; A61K-009/00; A61P-023/02; A61P-017/02</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017011377-A2&nbsp;</td><td>18&nbsp;Dec&nbsp;2018</td><td>C07C-233/09&nbsp;</td><td>201918&nbsp;</td><td>Pages: 22&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017011377-A2&nbsp;</td><td>BR10011377&nbsp;</td><td>30&nbsp;May&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10011377&nbsp;</td><td>30&nbsp;May&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">90356-0-0-0K M; 97261-0-0-0K M; 104328-1-0-0K M; 104479-0-0-0K M; 1062-0-0-0K M; 104492-0-0-0K M; 107779-0-0-0K M; 91821-0-0-0K M; 99084-0-0-0K M; 490-0-0-0K M; 861-0-0-0K M; K M; 132098-1-0-0K M; 4351-0-0-0K M; K M; 444-0-0-0; 133920-0-0-0</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">1852-S; 1859-S; 1870-S; 1863-S; 0009-S; 0113-S; 0137-S</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201909996J</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102016030412-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Foaming system to prevent formation of foam in shaken flasks and bioreactors and in growing of microorganism in process of fermentation, comprises support capable which is kept in liquid surface and covered by foaming agent</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">GELAIN L; DA COSTA A C</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2019100016</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Foaming system comprises support capable which is kept in liquid surface and covered by foaming agent.<br>USE - Foaming system used to prevent formation of foam in shaken flasks and bioreactors, in growing of microorganism in process of fermentation and to recover proteins trapped in foam in process of fermentation (all claimed).<br>ADVANTAGE - The foaming system minimizes accumulation, increases surface area and turbulence in liquid surface.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.); J01 (Separation - including evaporation, crystallisation, solvent extraction, chromatography, dialysis, osmosis including drying gases and/or vapours, and separation of solids from gases, liquids and other solids. Isotope separation, filter materials (including molecular sieves for separation), and centrifuges (except where used for analysis) (B01D, B03, B04, B07B).); A97 (Miscellaneous goods not specified elsewhere - including papermaking, gramophone records, detergents, food and oil well applications.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">D05-A03C; J01-D07; A04-G02E; A06-A00E; A06-A00E2; A12-W11</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">B01D-019/04; B01J-020/10</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102016030412-A2&nbsp;</td><td>04&nbsp;Dec&nbsp;2018</td><td>B01D-019/04&nbsp;</td><td>201918&nbsp;</td><td>Pages: 23&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102016030412-A2&nbsp;</td><td>BR10030412&nbsp;</td><td>21&nbsp;Dec&nbsp;2016</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10030412&nbsp;</td><td>21&nbsp;Dec&nbsp;2016&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">1013-0-0-0</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2019100016</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR132015007038-E2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Constructing attenuated mutant strain of pathogenic bacteria used in vaccine for inducing protection against bacterial disease such as salmonellosis, involves expressing gamma and bromodomain and extra-terminal proteins of bacteriophage</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">BROCCHI M; MILANEZ G P; WERLE C H</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2019139787</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Constructing attenuated mutant strain of pathogenic bacteria involves expressing gamma, bromodomain and extra-terminal (Bet) and Exo proteins of the bacteriophage present in plasmid pKD46, and promoting recombination of linear fragments in the target DNA. The allelic exchange of the HU gene coder is carried out by the recombination cassette comprising accessory gene and then the gene present in the recombination cassette is eliminated.<br>USE - Method for constructing attenuated mutant strain of pathogenic bacteria used in vaccine for inducing protection against bacterial disease such as salmonellosis and expressing antigens from other diseases.<br>ADVANTAGE - The method enables to construct attenuated mutant strain of pathogenic bacteria, which allows to provide immunization against salmonellosis and effective protection against salmonellosis in poultry.<br>DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:<br>(1) a vaccine vector has one KN-encoding gene knocked out and is capable of stimulating an immune response against an infection by a pathogenic bacterium; and<br>(2) vaccine comprises attenuated mutant strain of pathogenic bacteria, where the maturation corresponds to the deletion of both HU coding genes.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.); C06 (Biotechnology - including plant genetics and veterinary vaccines.); C02 (Heterocyclic.); ; D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B04-E99; B04-F10; B14-A01; B14-S11B1; B14-S11D2; B14-S12; C04-F10; C14-A01; C14-S11B1; C14-S11D2; C14-S12; D05-H07; D05-H12E; D05-H14A1; D05-H99</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61K-039/112; A61P-031/04; C12N-001/36; C12N-015/74; C12R-001/42</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR132015007038-E2&nbsp;</td><td>22&nbsp;Jan&nbsp;2019</td><td>A61K-039/112&nbsp;</td><td>201916&nbsp;</td><td>Pages: 22&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR132015007038-E2&nbsp;</td><td>BR13007038&nbsp;</td><td>30&nbsp;Mar&nbsp;2015</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR13007038&nbsp;</td><td>30&nbsp;Mar&nbsp;2015&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">200757-0-0-0K P</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2019139787</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017012543-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Method for probabilistic characterization of occurrence of phase slips in coherent optical systems, involves obtaining characteristics of phase slip, and determining mean time between occurrences and probability distribution of phase slip</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">APARECIDO BARBOSA F; DE ARRUDA MELLO D A</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C); PADTEC SA (PADT-Non-standard)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201913973T</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The method involves storing transmitted symbol sequence. The symbol sequence is obtained after phase recovery of received signal. Symbols errors (SE) are occurred through comparison of the symbol sequence and the received signal. Values of multiples of p added by phase are stored by received signal phase recovery algorithm, where the symbol sequence indicates locations. Predetermined number of consecutive erroneous symbols is detected. Initial position and final position of a block are detected. The initial position of the block is assigned to current position of a vector that stores positions of occurrence of phase slip. Probabilistic characteristics of the phase slip are obtained. Mean time between occurrences and probability distribution of the phase slip is determined.<br>USE - Method for probabilistic characterization of occurrence of phase slips in coherent optical systems.<br>ADVANTAGE - The method enables determining probability of occurrence and distribution of the phase slip to optimize correction process and identifying the symbol sequence is a simple manner.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a graphical view illustrating a method for probabilistic characterization of the occurrence of phase slips in coherent optical systems. '(Drawing includes non-English language text)'<br>Optical signal-to-noise ratio (OSNR)<br>Symbols errors (SE)<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">W01 (Telephone and Data Transmission Systems)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">W01-A01C</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">H04L-001/20</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017012543-A2&nbsp;</td><td>15&nbsp;Jan&nbsp;2019</td><td>H04L-001/20&nbsp;</td><td>201914&nbsp;</td><td>Pages: 35&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017012543-A2&nbsp;</td><td>BR10012543&nbsp;</td><td>13&nbsp;Jun&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10012543&nbsp;</td><td>13&nbsp;Jun&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201913973T</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017013663-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">High power microwave filter for use in radar, satellite and remote sensing system, has pass-band type element formed with coaxial resonant cavity, and filter assembly formed with metal cavity, separation walls and coaxial cavities</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">FONSECA L A C; DOS REIS E C; PRADO DE OLIVEIRA L; NETO J R M; FIGUEROA H E H</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C); BRADAR IND SA (BRAD-Non-standard)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201913971U</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The filter has a pass-band type element formed with a coaxial resonant cavity and operated based on microwave frequencies. A filter assembly is formed with a metal cavity (100), an input/output coupling (101a, 101b), coupling metal plates (102a-102c), coupling adjustment screws (104a-104c), an internal conductor (105a), a dielectric layer (105b), separation walls (106a-106c) and coaxial cavities. The separation walls are respectively formed with the coaxial cavities. A Teflon (RTM: PTFE) housing is fixed in the coaxial cavities.<br>USE - High power microwave filter for use in a radar, satellite and remote sensing system.<br>ADVANTAGE - The microwave filter is formed with the coaxial cavities, thus improving spurious performance of the filter in a simple manner.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of a high power microwave filter.<br>Metal cavity (100)<br>Input/output coupling (101a, 101b)<br>Coupling metal plates (102a-102c)<br>Coupling adjustment screws (104a-104c)<br>Internal conductor (105a)<br>Dielectric layer (105b)<br>Separation walls (106a-106c)<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">A85 (Electrical applications.); W02 (Broadcasting, Radio and Line Transmission Systems)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">A04-E08; A12-E; W02-A05A1E; W02-A05B1</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">H01P-001/20</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017013663-A2&nbsp;</td><td>15&nbsp;Jan&nbsp;2019</td><td>H01P-001/20&nbsp;</td><td>201914&nbsp;</td><td>Pages: 32&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017013663-A2&nbsp;</td><td>BR10013663&nbsp;</td><td>23&nbsp;Jun&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10013663&nbsp;</td><td>23&nbsp;Jun&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">104333-0-0-0</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201913971U</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102016030476-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Obtaining (4-((2',3',4'-O-triacetyl-alpha-L-rhamnosyloxy)-N- benzyl)hydrazine carbutamide) involves dissolving natural benzylisothiocyanate and 4-(4'-O-triacetyl-alpha-L-rhamnosyloxy) benzylisothiocyanate in dry dichloromethane</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">CHAVES H V; BEZERRA M M; BARBOSA F G; CASTRO DE ALMEIDA D K; MAFEZOLI J; DA SILVA M R; FILHO G C; DE PAULO TEIXEIRA PINTO V; DE CASTRO BRITO G A; NAPIMOGA J T C; VASCONCELOS AGUIAR L; OLIVEIRA DOS SANTOS A; ROCHA DO VAL D; LIMA DE ASSIS E; SILVEIRA F D; FERNANDES GOMES F I; CAPISTRANO FREITAS H; DE SOUZA DOS REIS T D; GOMES PEREIRA A M; CASTRO DA SILVA I I; BARROS BENEVIDES N M</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNIV FEDERAL CEARA (UYCE-Non-standard); UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2019100015</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Obtaining (4-((2',3',4'-O-triacetyl-alpha-L-rhamnosyloxy)-N-benzyl)hydrazine carbutamide) (MC-H) involves dissolving 30.0mg of 0.085mmol natural benzylisothiocyanate and 4-(4'-O-triacetyl-alpha-L-rhamnosyloxy) benzylisothiocyanate in 1.0mL dry dichloromethane, 11.0mg of 0.085mmol 4-dimethylaminopyridine, 80 mu l of 0.85mmol acetic anhydride and 118 mu l of 0.85mmol triethylamine to obtain reaction mixture. The reaction mixture is stirred at a speed of 100-500 revolutions per minute at room temperature for 3 hours until MC-H mixture is formed and is monitored with CCD. The solvent is removed from reaction medium by rotary evaporator to obtain reaction product. The reaction product is purified by 1.52g silica gel chromatography and by using 100mL hexane and ethyl acetate in a ratio of 3:2 as eluent to obtain purified product.<br>USE - Method for obtaining (4-((2',3',4'-O-triacetyl-alpha-L-rhamnosyloxy)-N- benzyl)hydrazine carbutamide) for treating algia (claimed).<br>DETAILED DESCRIPTION - The product is yield in an amount of 35.6mg having purity of 96%, and is subjected to another reaction which is carried out by dissolving 30.0mg of 0.085mmol product in 2mL dry tetrahydrofuran and 10 mu L of 0.17mmol hydrazine to obtain reaction mixture. The reaction mixture is stirred at 100-500rpm and ambient temperature for 24 hours to obtain reaction mixture. The obtained reaction mixture is added with 2.0mL distilled water, extracted with 5.0mL ethyl acetate for 3 times, dried with anhydrous sodium sulfate, and then solvent is removed in a rotary evaporator to obtain reacted product. The reacted product is purified by 2.5g silica gel chromatography and 100ml ethyl acetate as eluent.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B03 (Other heterocyclics.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B07-A02B; B14-C01</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">C07C-335/40; C07D-309/10; A61K-031/17; A61K-031/7042; A61P-029/00</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102016030476-A2&nbsp;</td><td>18&nbsp;Dec&nbsp;2018</td><td>C07C-335/40&nbsp;</td><td>201914&nbsp;</td><td>Pages: 23&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102016030476-A2&nbsp;</td><td>BR10030476&nbsp;</td><td>23&nbsp;Dec&nbsp;2016</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10030476&nbsp;</td><td>23&nbsp;Dec&nbsp;2016&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">244-0-0-0K U V; 570-0-0-0K U V; 76-0-0-0K U V; 4-0-0-0K S; K P</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">1208-U; 1013-U; 0840-S</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2019100015</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102016030480-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Obtaining N-(4-(4'-O-acetyl-alpha-L-rhamnosyloxy) benzyl)-2-(pyridinyl-4-carbonyl) hydrazine-1-carboxyamide involves dissolving natural isoniazid and 4-(4'-O-acetyl-L-rhamnosyloxy) benzylisothiocyanate in dry tetrahydrofuran</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">CHAVES H V; BEZERRA M M; BARBOSA F G; CASTRO DE ALMEIDA D K; MAFEZOLI J; DA SILVA M R; FILHO G C; DE PAULO TEIXEIRA PINTO V; DE CASTRO BRITO G A; NAPIMOGA J T C; VASCONCELOS AGUIAR L; OLIVEIRA DOS SANTOS A; ROCHA DO VAL D; LIMA DE ASSIS E; SILVEIRA F D; FERNANDES GOMES F I; CAPISTRANO FREITAS H; DE SOUZA DOS REIS T D; GOMES PEREIRA A M; CASTRO DA SILVA I I; BARROS BENEVIDES N M</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNIV FEDERAL CEARA (UYCE-Non-standard); UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2019100014</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Obtaining N-(4-(4'-O-acetyl-alpha-L-rhamnosyloxy) benzyl)-2-(pyridinyl-4-carbonyl) hydrazine-1-carboxyamide (MC-D7) involves dissolving 30.0mg of 0.085mmol natural isoniazid and 4-(4'-O-acetyl-L-rhamnosyloxy) benzylisothiocyanate in 2mL of dry tetrahydrofuran and 24mg of 0.17mmol isoniazid to obtain reaction mixture. The reaction mixture is stirred at a speed of 100-500 revolutions per minute and at ambient temperature for 24 hours until MC-D7 mixture is formed, and is monitored by CCD. The solvent is removed from reaction mixture on a rotary evaporator to obtain reaction product. The reaction product is purified by 2.83g silica gel in chromatography and using 100ml ethyl acetate and 120mL methanol in a ration of 3:1 as eluent.<br>USE - Method for obtaining N-(4-(4'-O-acetyl-alpha-L-rhamnosyloxy) benzyl)-2-(pyridinyl-4-carbonyl) hydrazine-1-carboxyamide used for treating algia (claimed).<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B03 (Other heterocyclics.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B07-A02B; B07-D04B; B14-C01</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">C07C-335/40; C07D-213/78; C07D-309/10; A61K-031/17; A61K-031/7042; A61P-029/00</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102016030480-A2&nbsp;</td><td>18&nbsp;Dec&nbsp;2018</td><td>C07C-335/40&nbsp;</td><td>201913&nbsp;</td><td>Pages: 22&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102016030480-A2&nbsp;</td><td>BR10030480&nbsp;</td><td>23&nbsp;Dec&nbsp;2016</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10030480&nbsp;</td><td>23&nbsp;Dec&nbsp;2016&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">539253-1-0-0K S; 7515-0-0-0K S; K P</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">0088-S</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2019100014</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102016030484-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Obtaining (4-(4'-O-acetyl-2',3'-O-bis(decanoyloxy)-alpha-L-rhamnosyloxy) benzylisothiocyanate) involves dissolving natural benzylisothiocyanate and 4-(4'-O-acetyl-2',3'-rhamnosyloxy) benzylisothiocyanate in dry dichloromethane</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">CHAVES H V; BEZERRA M M; BARBOSA F G; CASTRO DE ALMEIDA D K; MAFEZOLI J; DA SILVA M R; FILHO G C; DE PAULO TEIXEIRA PINTO V; DE CASTRO BRITO G A; NAPIMOGA J T C; VASCONCELOS AGUIAR L; OLIVEIRA DOS SANTOS A; ROCHA DO VAL D; LIMA DE ASSIS E; SILVEIRA F D; FERNANDES GOMES F I; CAPISTRANO FREITAS H; DE SOUZA DOS REIS T D; GOMES PEREIRA A M; CASTRO DA SILVA I I; BARROS BENEVIDES N M</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNIV FEDERAL CEARA (UYCE-Non-standard); UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2019100013</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Obtaining (4-(4'-O-acetyl-2',3'-O-bis(decanoyloxy)-alpha-L-rhamnosyloxy) benzylisothiocyanate) (MC-D9) involves dissolving 30.0mg of 0.085mmol natural benzylisothiocyanate and 4-(4'-O-acetyl-2',3'-rhamnosyloxy) benzylisothiocyanate in 1.0mL dry dichloromethane, 11.0mg of 0.085mmol 4-dimethylaminopyridine (DMAP) and 88.0 mu l of 0.425mmol dodecanoyl chloride to obtain a reaction mixture. The reaction mixture is stirred at a speed of 100-500 revolutions per minute and ambient temperature for 24 hours until MC-D9 mixture is formed. The solvent is removed from obtained mixture by rotary evaporator, and is) purified in chromatography on 1.98g silica gel by using 100mL of hexane/ethyl acetate in a ratio of (9:1) as eluent.<br>USE - Method for obtaining (4-(4'-O-acetyl-2',3'-O-bis(decanoyloxy)-alpha-L-rhamnosyloxy) benzylisothiocyanate used for treating algia (claimed).<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B03 (Other heterocyclics.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B07-A02B; B14-C01</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">C07C-331/24; A61K-031/7024; A61K-031/17</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102016030484-A2&nbsp;</td><td>18&nbsp;Dec&nbsp;2018</td><td>C07C-331/24&nbsp;</td><td>201913&nbsp;</td><td>Pages: 22&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102016030484-A2&nbsp;</td><td>BR10030484&nbsp;</td><td>23&nbsp;Dec&nbsp;2016</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10030484&nbsp;</td><td>23&nbsp;Dec&nbsp;2016&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">8171-0-0-0K S; 80761-0-0-0K S; 76243-0-0-0K S; 7575-0-0-0K S; 6650-0-0-0K S; 8421-0-0-0K S; 7880-0-0-0K S; 107016-0-0-0K U V; 570-0-0-0K U V; K P</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">0442-S; 1694-U</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2019100013</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR132017006605-E2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Identifying nuclear magnetic resonance and chemometrics of biomarkers for severe mental illness involves diluting human serum, transferring sample to nuclear magnetic resonance tube, and obtaining 1H nuclear magnetic resonance spectra</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">TASIC L; JESUS POPPI R; HAYASHI M A F; BRIETZKE E; TAVARES DE LACERDA A L</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201910008X</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Identifying nuclear magnetic resonance (NMR) and chemometrics of biomarkers for severe mental illness involves diluting human serum, transferring the sample to NMR tube, obtaining 1H NMR spectra at 25 degrees C, obtaining 1H T2-edited NMR spectra, obtaining heteronuclear single-quantum correlation spectroscopy (HSQC)-type 2-dimensional-heteronuclear spectra (13C, 1H), forming a data matrix of the obtained 1H NMR spectra, performing chemometric analysis applied to the pre-processing of data by self-escalation, finding the variables obtained by chemometric analysis in the data obtained by 1H NMR spectra, finding the coupling standards for the biomarkers obtained by finding the variables in the obtained HSQC-type 2D-heteronuclear spectra, and validating the identification of biomarkers.<br>USE - Method for identifying NMR and chemometrics of biomarkers for severe mental illness used for evaluating metabolic profiles of human serum, classifying patients by 1H NMR analysis and monitoring and studying the drug effects and the pharmacological effects on the treatment applied (claimed), where mental illness is a bipolar disorder or schizophrenia.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); S03 (Scientific Instrumentation)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B04-B04D4; B11-C08A; B12-K04E3; B12-K04G; S03-E07C; S03-E09; S03-E14H</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G01N-033/68</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR132017006605-E2&nbsp;</td><td>26&nbsp;Dec&nbsp;2018</td><td>G01N-033/68&nbsp;</td><td>201912&nbsp;</td><td>Pages: 17&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR132017006605-E2&nbsp;</td><td>BR13006605&nbsp;</td><td>28&nbsp;Mar&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR13006605&nbsp;</td><td>28&nbsp;Mar&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201910008X</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR8603210-Y1</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Device for drainage of gaseous or liquid pleural fluids released during aortic disorders in hospital and pre-hospital care, comprises the rigid conical geometric body that is provided with the first extended end</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">TINCANI A J; BARRETO G</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2019100045</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The device (1) comprises a rigid conical geometric body (2) that is provided with a first extended end (4), where first extended end is provided with a ring with holes for engaging with an additional cover device (3). First space (A) is formed between the additional cover device. An outer upper end of a central duct (7) is coupled with a flexible conductive pipe. Second space (B) is provided in a rear portion of a sealing valve (9).<br>USE - Device for drainage of gaseous or liquid pleural fluids released during aortic disorders, such as trauma, pneumothorax, hemothorax or effusions in hospital and pre-hospital care.<br>ADVANTAGE - The device includes a first space that is formed between the additional cover device, and thus easy and efficient removal of the liquids is ensured.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of a device for drainage of gaseous or liquid pleural fluids used in hospital and pre-hospital care.<br>Device for drainage of gaseous or liquid pleural fluids used in hospital and pre-hospital care (1)<br>Rigid conical geometric body (2)<br>Additional cover device (3)<br>First extended end (4)<br>Central duct (7)<br>Sealing valve (9)<br>First space (A)<br>Second space (B)<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">P34 (Sterilising, syringes, electrotherapy (A61L, M, N).)</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61M-001/04</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR8603210-Y1&nbsp;</td><td>26&nbsp;Dec&nbsp;2018</td><td>A61M-001/04&nbsp;</td><td>201910&nbsp;</td><td>Pages: 20&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR8603210-Y1&nbsp;</td><td>BR003210&nbsp;</td><td>21&nbsp;Dec&nbsp;2006</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR003210&nbsp;</td><td>21&nbsp;Dec&nbsp;2006&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RCKE7RM N; R05378K M; R21758K M; RA06JYK M; R20580K M; RCAB09K M; RAFR2SK M; RA00NSN; RA012PN; RA00GTK P; RBEPK8K M; RB8PCOK M; RA0KN8K M; RA00NGK M; RA040VK M; RA014AK M; R07373K M; RA01PMK M; RA01SBK M; R00148K M; RA0DQKK M; RA80GPK M; RA0EW7K M; R10127K M; RA1CJWK M; R01117K M; R18464K M; R03215K M; R00648K M; RA21R9K M; R07915K M; R19211K M; RA04J1K M; R16377K M; R17032K M; R03882K M; R01694K M; RA00CAK M; R00975K M; R07226; R00351; R00370; RA6A61K M; R01058K P; RA5FZQK P; R01046K S; R00651K S; R00840K S; RA023TK U V; R00479; R01706K P Q; R00278K P Q; R01680K P Q; R00345K P Q; R01722K P Q; R01744K P Q; R01135K P Q; R00480K P Q; R01654K P Q; R04644K P Q; R01391K P Q; R01594K P Q; RCJMBSK P Q; RALLSIK P Q; R04406K P Q; R08869K P Q; R15616K P Q; RBFMMSK P Q; RAAT65K P Q; R01760K S; RA05YAK S; R01852K M; R01859K M; RA016GK M; R01870K M; RA00D5K M; RA01EAK M; R01863K M; RA002WK M; R11382K M; R00113K M; R00137K M; RCJJCWK M; R09927K M; R08919K M; RCJJCXK M; R00326; R01208K U V; R08498K U V; R01013K U V; RCJ6N6K P; RA710KK S; R00088K S; RA28UFK S; RA3UHOK S; RAEF9OK S; RA65SLK S; RA0YBYK S; RA0ONBK S; R00442K S; RCJ6MBK P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2019100045</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr>
<style type="text/css">
        table.FR_table_borders {-webkit-box-sizing: border-box; -moz-box-sizing: border-box;box-sizing: border-box; margin-top: 2px; outline: 1px solid #bababa; border-collapse: collapse;}
        table.FR_table_noborders .fr_address_row2:last-child {width: 100%}
        table.FR_table_borders th {vertical-align: middle; padding: 9px 10px 9px 9px;background: #f3f3f3; text-align: left;font-weight: bold;}
        table.FR_table_borders td {vertical-align: middle; padding: 5px;}
        table.FR_table_borders th, table.FR_table_borders td {border: 1px solid #CCCCCC; }
    </style><tr xmlns:date="http://exslt.org/dates-and-times" xmlns:str="http://exslt.org/strings" xmlns:exsl="http://exslt.org/common" xmlns:set="http://exslt.org/sets">
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102014011059-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Method for automatic classification of echocardiograms, involves providing dense sample, and generating space of quantized features so as to determine set of visual words resulting in creation of visual directory</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">BIZETTO PENATTI O A; DE OLIVEIRA WERNECK R; RODRIGUES DE ALMEIDA W; VECCHIA STEIN B; VATANABE PAZINATO D; MENDES P R</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">SAMSUNG ELETRONICA DA AMAZONIA LTD (SMSU-C); UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201910001S</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The method involves providing a dense sample (103) that is arranged with a set of large regions and with a set of small regions (104). The set of small regions is provided with a local invariant descriptor. A feature space (202) is determined in the dense sample, and a quantification step is performed for quantification of the feature space. A space of quantized features is generated so as to determine a set of visual words resulting in the creation of a visual directory (205) that is coded and pooled (106).<br>USE - Method for automatic classification of echocardiograms.<br>ADVANTAGE - The space of quantized features is generated so as to determine the set of visual words resulting in the creation of the visual directory, thus allowing introduction of visual word bag, allowing automatic classification of the cardiac output in real-time, allowing easy analysis of the heart structure, and allowing understanding of possible cardiac diseases.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a schematic illustration of calculation of image representation using a visual dictionary. '(Drawing includes non-English language text)'<br>Dense sample (103)<br>Small regions (104)<br>Step for pooling a visual directory (106)<br>Feature space (202)<br>Visual directory (205)<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">P31 (Diagnosis, surgery (A61B).); T01 (Digital Computers)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">T01-J05B2; T01-J06A; T01-J10B2; T01-J11A1</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G06T-007/00; A61B-005/00</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102014011059-A2&nbsp;</td><td>04&nbsp;Dec&nbsp;2018</td><td>G06T-007/00&nbsp;</td><td>201910&nbsp;</td><td>Pages: 38&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102014011059-A2&nbsp;</td><td>BR10011059&nbsp;</td><td>07&nbsp;May&nbsp;2014</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10011059&nbsp;</td><td>07&nbsp;May&nbsp;2014&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201910001S</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017001719-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Method for generating thermoelectric power from e.g. charcoal, involves cooling produced gas in equipment at temperature to decrease concentration of alkali compounds, recovering energy from chain, and compressing stream in compressor</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">DE SOUZA SANTOS M L</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2019100012</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The method involves feeding a solid particulate fuel to a fluidized bed dryer (D) through an endless thread (FE), and receiving a hot gas from a discharge part of gas turbine. Dry solid fuel (DF) from the dryer is mixed with crude glycerol to form a slurry that is pumped through the pump (FS) to a pressurized gasifier (G), where gas produced by the pressurized gasifier passes through cyclones (CY) and filters for admission to gas turbines. The produced gas is cooled in equipment (11) at temperatures below corresponding dew points to decrease the concentration of alkali compounds in gas stream (4) to acceptable values for injection in gas turbines. Energy is recovered from chain (5), and gas stream (15) is compressed in a compressor (CD) and followed with gas stream (28) to the dryer.<br>USE - Method for generating thermoelectric power from solid fuels e.g. charcoal, litter, and biomass.<br>ADVANTAGE - The method enables simplifying the feeding of particulate solids to reactors or pressurized environments and generating high efficiency thermoelectric power from the solid fuels. The method enables consuming excess glycerol from biodiesel production, which is largely discarded or simply incinerated and avoiding the waste of the glycerol.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view illustrating a method of generating thermoelectric power from solid fuels. '(Drawing includes non-English language text)'<br>Compressor (CD)<br>Cyclones (CY)<br>Fluidized bed dryer (D)<br>Dry solid fuel (DF)<br>Endless thread (FE)<br>Pump (FS)<br>Pressurized gasifier (G)<br>Gas stream (4)<br>Chain (5)<br>Equipment (11)<br>Gas streams (15, 28)<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">Q52 (Reaction engines: external combustion; gas turbines; rockets (F01D, F02C, F02K, F02M)); U14 (Memories, Film and Hybrid Circuits); X15 (Non-Fossil Fuel Power Generating Systems)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">U14-E05A1; X15-D</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">F02C-006/00; H02N-011/00</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017001719-A2&nbsp;</td><td>04&nbsp;Dec&nbsp;2018</td><td>F02C-006/00&nbsp;</td><td>201910&nbsp;</td><td>Pages: 20&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017001719-A2&nbsp;</td><td>BR10001719&nbsp;</td><td>27&nbsp;Jan&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10001719&nbsp;</td><td>27&nbsp;Jan&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2019100012</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017006793-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Nanoemulsion applied in treatment of psoriasis, atopic dermatitis, comprises hydrogenated soybean lecithin as surfactant, nonionic surfactant, medium chain thyroglyceride, ethanol, cyclosporin A, glycerol, tocopherol, and water</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">PESSINE F B T; KUBOTA D</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201895030B</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Nanoemulsion comprises 1.5-3 wt.% hydrogenated soybean lecithin as surfactant, 1.5-4 wt.% nonionic surfactant, 4-7 wt.% TCM, 9-40 wt.% ethanol, 0.5-8 wt.% cyclosporin A, 2-3 wt.% glycerol, 0.1-1 wt.% tocopherol, and 60-80 wt.% water.<br>USE - Nanoemulsion used for the preparation of a composition for parenteral use, applied in the treatment of psoriasis, atopic dermatitis, diabetes mellitus for immunosuppression (all claimed).<br>DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for preparing nanoemulsion, which involves:<br>(A) preparing oil phase by using 1.5-3% hydrogenated soybean lecithin with adsorptive, relative to the total mass of the nanoemulsion, 4-7% TCM in relation to the total dananeemulsion mass, 9-40% ethanol (volume: mass) total nanoemulsion kneading, 0.5-8% cyclosporin A relative to mass of MCT;<br>(B) preparing aqueous phase by using 1.5-4% nonionic surfactant, 0.1-1% de-tocopherol, 2-3% glycerol, 60-80% water, heating each phase separately at 50-63 degrees C, preferably 53 degrees C;<br>(C) adding phaseolose in the aqueous phase under constant stirring to homogenize the phases separately preferably by using a magnetic stirrer rotating between 400-600 revolution per minute, preferably 600 revolution per minute, heating at 50-63 degrees C, preferably 53 degrees C;<br>(D) reversing phaseoleose in the aqueous phase under constant stirring, preferably using a rotor-stator type homogenizer at a speed of 3200-4200 revolution per minute, preferably 320 revolution per minute for 2-5 minutes, preferably 3 minutes and a temperature between 53-70 degrees C;<br>(E) keeping obtained pre-emulsion at cooling and system organization;<br>(F) keeping obtained pre-emulsion under cooling, defrost bathing at a temperature between 7-15 degrees C, preferably 10 degrees C;<br>(G) homogenizing preemulsion by the high deemulsification energy method using a selected apparatus from a high pressure homogenizer, a microfluidizer, and a tipped sonicator, preferably a tipped sonicator;<br>(H) evaporating solvent of the nanoemulsion, preferably under reduced pressure;<br>(I) adjusting pH between 6.5 and 8.0, preferably 7.0 with aqueous aquasic solution, preferably 0.1M NaOH in order to maintain the physicochemical integrity of the NEs to usoparenteral; and<br>(J) obtaining nanosemulsion with mean diameter in the range 66.2 plus minus 2, 1 nanometer at 230 plus minus 7.9 nanometer, polydispersity index in the range of 0.1-0.240, and efficiency between 80-95% in thecapsulation of cyclosporin A.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.); B02 (Fused ring heterocyclics.); B03 (Other heterocyclics.); B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); </td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B02-C01; B04-A08G2; B04-A10; B04-B01B; B04-C03C; B05-A01B; B05-B01P; B10-C04E6; B10-E04C; B10-G02; B12-M03; B12-M11Q; B14-C03; B14-G01; B14-N17C; B14-S04; B14-S18; B15-E00; A05-H03; A05-H04; A10-E07; A10-E08A; A10-E08B; A12-V01; A12-W05; A12-W14</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61K-009/107; A61K-047/24; A61K-038/13; A61P-017/06; A61P-017/00; A61P-003/10; A61P-037/00</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017006793-A2&nbsp;</td><td>30&nbsp;Oct&nbsp;2018</td><td>A61K-009/107&nbsp;</td><td>201908&nbsp;</td><td>Pages: 62&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017006793-A2&nbsp;</td><td>BR10006793&nbsp;</td><td>29&nbsp;Mar&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10006793&nbsp;</td><td>29&nbsp;Mar&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">109103-0-0-0K M; 109113-0-0-0K M; 109114-0-0-0K M; 490-0-0-0K M; 109110-0-0-0K M; 109111-0-0-0K M; 17530-0-0-0K M; 2-1-0-0K M; 99222-0-0-0K M; 104477-1-0-0K M; 90981-1-0-0K M; 444-0-0-0; 238-0-0-0</td>
</tr><tr>
<td valign="top"><B>MN </B></td><td>212465701 K M</td>
</tr><tr>
<td valign="top"><B>RI</B></td><td valign="top">63917</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">1693-S; 0113-S; 1163-S; 0990-S; 1514-S; 1833-S; 1869-S</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201895030B</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR122012005794-B1</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Synthesizing dobaclofen analogues involve obtaining 2-cyclopentyloxy-4-nitroanisole from reaction of 2-methoxy-5-nitrophenol with bromo-cyclopentane, performing catalytic hydrogenation of 2-cyclopentyloxy-4-nitroanisole</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">CORREIA C R D; GARCIA A L L</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2018A1570B</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Synthesizing dobaclofen analogs involve obtaining 2-cyclopentyloxy-4-nitroanisole from the reaction of 2-methoxy-5-nitrophenol with bromo-cyclopentane, performing catalytic hydrogenation of 2-cyclopentyloxy-4-nitroanisole to give 3-cyclopentyloxy-4-methoxyaniline, performing diazotation reaction of 3-cyclopentyloxy-4-methoxyaniline to obtain 3-cyclopentyloxy-4-methoxy-benzenediazonium tetrafluoroborate, performing Heck-Matsuda reaction of 3-cyclopentyloxy-4-methoxy-benzenediazonium tetrafluoroborate with N-Boc-3-pyrroline to give 1-(t-butoxycarbonyl)-4-(3-cyclopentyloxy-4-methoxyphenyl) -pyrrolidin-2-ol, oxidixing 1-(t-butoxycarbonyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-pyrrolidin-2-ol to obtain 1-(t-butoxycarbonyl) -4- (3-cyclopentyloxy-4-methoxyphenyl)-pyrrolidin-2-one, hydrolysing 1-(t-butoxycarbonyl) -4- (3-cyclopentyloxy-4-methoxyphenyl)-pyrrolidin-2-one in acidic medium with 6N HCl to give 4-amino-3-(3-hydroxy-4-methoxyphenyl) butyric acid hydrochloride (I).<br>USE - Method for synthesizing dobaclofen analogues.<br>DETAILED DESCRIPTION - The method further involves hydrolysing 1-(t-butoxycarbonyl) -4- (3-cyclopentyloxy-4-methoxyphenyl)-pyrrolidin-2-one in basic medium with LiOH in THF/H2O (2: 1) followed by acid deprotection of the amino group to give the compound 4-amino-3-(3-cyclopentyloxy- 4-methoxyphenyl) butyric acid (II). The method for synthesizing dobaclofen analogs of formulae (I-II) involve obtaining 2-cyclopentyloxy-4-nitroanisole from the reaction of 2-methoxy-5-nitrophenol with bromo-cyclopentane, performing catalytic hydrogenation of 2-cyclopentyloxy-4-nitroanisole to give 3-cyclopentyloxy-4-methoxyaniline, performing diazotation reaction of 3-cyclopentyloxy-4-methoxyaniline to obtain 3-cyclopentyloxy-4-methoxy-benzenediazonium tetrafluoroborate, performing Heck-Matsuda reaction of 3-cyclopentyloxy-4-methoxy-benzenediazonium tetrafluoroborate with N-Boc-3-pyrroline to give 1-(t-butoxycarbonyl)-4-(3-cyclopentyloxy-4-methoxyphenyl) -pyrrolidin-2-ol, oxidixing 1-(t-butoxycarbonyl)-4-(3-cyclopentyloxy-4-methoxyphenyl)-pyrrolidin-2-ol to obtain 1-(t-butoxycarbonyl) -4- (3-cyclopentyloxy-4-methoxyphenyl)-pyrrolidin-2-one, hydrolysing 1-(t-butoxycarbonyl) -4- (3-cyclopentyloxy-4-methoxyphenyl)-pyrrolidin-2-one in acidic medium with 6N HCl to give 4-amino-3-(3-hydroxy-4-methoxyphenyl) butyric acid hydrochloride (I), or hydrolysing 1-(t-butoxycarbonyl) -4- (3-cyclopentyloxy-4-methoxyphenyl)-pyrrolidin-2-one in basic medium with LiOH in THF/H2O (2: 1) followed by acid deprotection of the amino group to give the compound 4-amino-3-(3-cyclopentyloxy- 4-methoxyphenyl) butyric acid (II)..<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.); A96 (Medical, dental, veterinary, cosmetic.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B05-C07; B10-B02E; A04-B10; A04-C; A12-L04A; A12-M03; A12-V00V; A12-V01; N02-F01; N02-F04; N07-B02; N07-D03</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">C07C-227/22; C07C-229/34; A61K-031/195; A61P-021/00</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR122012005794-B1&nbsp;</td><td>04&nbsp;Sep&nbsp;2018</td><td>C07C-227/22&nbsp;</td><td>201908&nbsp;</td><td>Pages: 16&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR122012005794-B1&nbsp;</td><td>BR12005794&nbsp;</td><td>11&nbsp;Sep&nbsp;2002</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR12005794&nbsp;</td><td>11&nbsp;Sep&nbsp;2002&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">710077-0-0-0K S; 8233-0-0-0K S; 68-0-0-0K U V; 114-0-0-0K U V; 107367-0-0-0K U V; 9-0-0-0K U V; 255-0-0-0K U V; 107348-0-0-0K U V; 129423-0-0-0K U V; 17-0-0-0K U V; 147083-0-0-0K U V; 71-0-0-0C K; 2211-0-0-0C K; 1803-0-0-0C K; K P; K P</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">1391-U; 1706-U; 1744-U; 1704-U; 1066-U; 1697-U; 1973-U; 1534-U; 1513-U; 1669-S</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2018A1570B</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102012026981-A2; BR102012026981-B1</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Modifying chemical composition or lignifying Eucalyptus wood, involves performing dissolution of naringenin-chalcone in solvent capable of diluting naringenin with flavonoids and then performing dissolution of solution</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">PEREIRA G A G; LEPIKSON J; GUIMARAES PEREIRA G A; NETO J L</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNIC-Non-standard); INT PAPER BRASIL LTDA (ITPA-Non-standard)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201524705A</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Modifying chemical composition of or lignifying Eucalyptus wood, involves performing dissolution of naringenin-chalcone in a solvent capable of diluting naringenin with flavonoids and then performing dissolution of solution in a nutrient solution for plant nutrition. The nutrient solution with fertilizers is applied on Eucalyptus wood.<br>USE - Method for modifying chemical composition or lignifying Eucalyptus wood (all claimed).<br>ADVANTAGE - The method enables to modify chemical composition or lignifying Eucalyptus wood, which is suitable for utilization in paper industry and for generation of energy.<br>DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a composition for chemical modification of Eucalyptus wood.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">C04 (Fertilisers - including urea and phosphoric acid production. Also soil modifiers and plant growth media. Chemical aspects of compost production.); F09 (Paper-making production of cellulose, chemical treatment of wood - including chipboard and fibre-board (D21).)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">C06-A01; C10-F02; C12-M07; C14-T; C14-U01; F05-A06</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A01N-043/16; A01P-021/00; C07D-311/32</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102012026981-A2&nbsp;</td><td>02&nbsp;Dec&nbsp;2014</td><td>C07D-311/32&nbsp;</td><td>201536&nbsp;</td><td>Pages: 37&nbsp;</td><td>&nbsp;</td>
</tr>
<tr>
<td>BR102012026981-B1&nbsp;</td><td>11&nbsp;Dec&nbsp;2018</td><td>A01N-043/16&nbsp;</td><td>201908&nbsp;</td><td>&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102012026981-A2&nbsp;</td><td>BR10026981&nbsp;</td><td>22&nbsp;Oct&nbsp;2012</td>
</tr>
<tr>
<td>BR102012026981-B1&nbsp;</td><td>BR10026981&nbsp;</td><td>22&nbsp;Oct&nbsp;2012</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10026981&nbsp;</td><td>22&nbsp;Oct&nbsp;2012&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">6569-2-0-0K M; 6763-0-0-0K M</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">0611-S</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201524705A</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017004792-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Coating phase change material in storage of solar energy, textile materials and building industry, involves producing phase change material particles in polymer solution, and coating phase change material particles in fluidized bed</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">BARBON PAULO B; SILVA PRATA A</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201895034F</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Coating phase change material particles in fluidized bed, involves producing phase change material particles in polymer solution, and coating phase change material particles in fluidized bed.<br>USE - Coating phase change material in storage of solar energy, textile materials, building industry, and active food packaging (claimed).<br>ADVANTAGE - The method enables to coating phase change material in field of civil engineering and active food packaging.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">A32 (Polymer fabrication - such as moulding, extrusion, forming, laminating, spinning.); A11 (Polysaccharides; natural rubber; other natural polymers (only a restricted range of (modified) natural polymers are included. Thus starch would be excluded, but chemically modified starch included).); A88 (Mechanical engineering and tools e.g. valves, gears and conveyor belts.); A92 (Packaging and containers - including ropes and nets.); A93 (Roads, building, construction flooring.); A97 (Miscellaneous goods not specified elsewhere - including papermaking, gramophone records, detergents, food and oil well applications.); </td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">A12-E11B; A12-P01; A12-R01; A12-W09; A12-W16; F03-C</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A23L-029/30; A23P-020/18; B29C-047/00; C08J-007/04; D21H-017/31</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017004792-A2&nbsp;</td><td>30&nbsp;Oct&nbsp;2018</td><td>A23L-029/30&nbsp;</td><td>201906&nbsp;</td><td>Pages: 31&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017004792-A2&nbsp;</td><td>BR10004792&nbsp;</td><td>08&nbsp;Mar&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10004792&nbsp;</td><td>08&nbsp;Mar&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">133925-0-0-0; 104328-1-0-0; 92830-0-0-0; 107779-0-0-0; 96536-0-0-0</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201895034F</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017004725-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Identifying biomarkers related to cystic afibrose for identification of F508del amutation, involves obtaining saliva samples, centrifuging samples and filtering to obtain supernatant, and saliva molecules are extract</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">CATHARINO R R; ESTEVES C Z; DE OLIVEIRA D N; DELAFIORI J; DE AGUIAR DIAS L; RODRIGUES MELO C F; SOUZA GOMEZ C C; MAUCH R M; AIELLO T B; RIBEIRO J D; FERNANDO RIBEIRO A; LEVY C E</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201895034J</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Identifying biomarkers related to cystic afibrose (CF) involves obtaining a saliva samples, centrifuging the samples and filtering to obtain the supernatant. The saliva molecules are extract with methanol and filter the samples, than add a weak base to analyze the samples by mass spectrometry electron spray (ESI-MS) to identify the fibroblasts of CF.<br>USE - Method for identifying biomarkers related to cystic afibrose (CF) for identification of F508del amutation (claimed).<br>ADVANTAGE - The method enables to identify biomarkers related to cystic afibrose (CF), which has assists in diagnosis of potential FC, and determined concentration of ions and oxidative stress and large-scale uncollected collection, and does not present a possibility of storage for later analyzes.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.); B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).); S03 (Scientific Instrumentation)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">A04-E10B; A12-V03C2; A12-W11A; B04-B04G; B04-C03; B04-F02; B04-N16; B11-C08A; B11-C08B; B12-K04G; J04-B01A1; J04-C01; S03-E09F; S03-E14H</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G01N-033/50; G01N-033/68</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017004725-A2&nbsp;</td><td>30&nbsp;Oct&nbsp;2018</td><td>G01N-033/50&nbsp;</td><td>201906&nbsp;</td><td>Pages: 23&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017004725-A2&nbsp;</td><td>BR10004725&nbsp;</td><td>09&nbsp;Mar&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10004725&nbsp;</td><td>09&nbsp;Mar&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">125155-0-0-0K M; 6112-0-0-0</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201895034J</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017006471-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Solid lipid nanoparticles in foods or food grade products such as low Sat products, margarines, chocolates, biscuit fillings, animal feeds, comprise lipid phase and aqueous phase, where aqueous phase comprising drinking water and emulsifier</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">DA SILVA SANTOS V; SANTANA M H A; BADAN RIBEIRO A P</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2018950310</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Solid lipid nanoparticles comprise 5-15 wt.% total lipid phase and 85 to 95 wt.% aqueous phase, where aqueous phase comprising drinking water and 0.5 to 10 wt.% emulsifiers and the lipid phase comprising solid lipids.<br>USE - The solid lipid nanoparticles in foods or food grade products such as low Sat products, margarines, chocolates, biscuit fillings, animal feeds, beverages, sauces, ice cream syrups, dairy products, biofilms for drying of surfaces, packaging, fruits and vegetables (all claimed).<br>ADVANTAGE - The solid lipid nanoparticles reduces the level of saturated fatty acids in food, improves the structural properties of food or products and enriches product or foods with bioactive compounds.<br>DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for preparing solid lipid nanoparticles and nanostructured lipid carriers, which involves Fusing the lipid fraction, forming Emulsion formation, nanoemulsifying in polycyclic aromatic hydrocarbons and Lipid crystallizing.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">D03-C02; D03-H02B2</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A23D-007/04</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017006471-A2&nbsp;</td><td>30&nbsp;Oct&nbsp;2018</td><td>A23D-007/04&nbsp;</td><td>201904&nbsp;</td><td>Pages: 39&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017006471-A2&nbsp;</td><td>BR10006471&nbsp;</td><td>29&nbsp;Mar&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10006471&nbsp;</td><td>29&nbsp;Mar&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2018950310</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR132015004540-E2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Use of silver nanoparticles for treating textile products affected Xanthomonas axonopodis</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">TASIC L; BALLOTIN D P M; DURAN CABALLERO N E; TSUKAMOTO J; GASPARI P D M</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C); UNIV MOGIANA ORG EDUCACAO &amp; CULTURA (UYMO-Non-standard)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2018950278</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Use of silver nanoparticles is claimed for treating Xanthomonas axonopodis pv. citri.<br>USE - Silver nanoparticles used for treating textile products affected with Xanthomonas axonopodis pv. citri.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.); M22 (Casting; powder metallurgy - including foundry moulding, moulding machines, patterns, moulds, cores and metal casting (B22).); A97 (Miscellaneous goods not specified elsewhere - including papermaking, gramophone records, detergents, food and oil well applications.); F06 (Chemical-type treatment of textiles (D06B, L, M, P, Q).); P53 (Metal casting, powder metallurgy (B22).)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">D05-H; M22-H01; M22-H02; A03-A05A; A08-M02; A12-S05R; A12-W04C; A12-W12F; F03-C; F03-E01</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">D06M-011/83; D06M-011/84; D06M-016/00; D06M-023/08; A01N-059/16; B22F-009/24</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR132015004540-E2&nbsp;</td><td>16&nbsp;Oct&nbsp;2018</td><td>D06M-011/83&nbsp;</td><td>201904&nbsp;</td><td>Pages: 15&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR132015004540-E2&nbsp;</td><td>BR13004540&nbsp;</td><td>26&nbsp;Feb&nbsp;2015</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR13004540&nbsp;</td><td>26&nbsp;Feb&nbsp;2015&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">192545-0-0-0; 90356-0-0-0; 856-0-0-0</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2018950278</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">WO2018227261-A1; BR102017012768-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Obtaining nanostructured complex involves preparing dibasic ammonium phosphate in situ in presence of ammonia and orthophosphoric acid in mechanical homogenizer until neutralization, mixing magnesium chloride and dibasic ammonium phosphate</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">FAVARO W J; CABALLERO N E D; DURAN CABALLERO N E</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2018A2140M</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Obtaining nanostructured complex (CFI-1) involves preparing dibasic ammonium phosphate in situ in the presence of ammonia and orthophosphoric acid in a mechanical homogenizer with a minimum power of 500W in a temperature range of 25-55 degrees C until neutralization, mixing 1-3 wt.% magnesium chloride and 1-4 wt.% dibasic ammonium phosphate at 22-30oC at a speed of 10000 revolution per minute, applying a pressure plate in the mixture obtained in a high pressure homogenizer with the homogenization valve with a variable pressure between 400-700 bar, preferably 600 bar, in the second stage the homogenization valve with variable pressure between 50-70 bar, preferably 60 bar, for up to 1-3 cycles, preferably 2 cycles, cooling the suspension obtained to a temperature range comprised between 0-20 degrees C, preferably 15 degrees C, precipitating, and washing the crystals with sterile, distilled water and drying in a temperature range of 30-40 degrees c, preferably 37 degrees C for 24-72 hours, preferably 48 hours.<br>USE - Method for obtaining nanostructured complex (CFI-1) for treating cancer, where the cancer is prostate, bladder, colorectal, mastocytoma, and lymphoma (all claimed).<br>DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for obtaining a nanostructured protein-associated complex (MRB-CFI-1), which involves<br>(A) preparing dibasic ammonium phosphate in situ in the presence of ammonia and orthophosphoric acid in a mechanical homogenizer with a minimum power of 500W at a temperature of 25-55 degrees C until neutralization;<br>(B) mixing 1-3 wt.% magnesium chloride and 1-4 wt.% dibasic ammonium phosphate obtained at 22-30 degrees C, preferably 25 degrees C, adjusting pH to 5-7, preferably 6, in a mechanical homogenizer in a variable rotation range between 7000-15000 revolutions per minute, preferably 10000 revolutions per minute;<br>(C) adding protein at a concentration of 0.5-1.5 wt.% to the complex obtained and applying a pressure plate in the mixture obtained in a high pressure homogenizer with the homogenization valve with a variable pressure between 400-700 bar, preferably 600 bar, in the second stage the homogenization valve with variable pressure between 50-70 bar, preferably 60 bar, for up to 1-3 cycles, preferably 2 cycles, cooling the suspension obtained in a temperature range comprised between 0-20 degrees C, preferably 15 degrees C, precipitating; and<br>(D) washing the crystals with distilled sterile water and dry at a temperature of 30-40 degrees C, preferably at 37 degrees C, in a time interval of 24-72 hours, preferably 48 hours.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); B06 (Inorganics - including fluorides for toothpastes etc.); D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.); A96 (Medical, dental, veterinary, cosmetic.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B04-L05B; B05-A01B; B05-B02A2; B05-B02A3; B05-C07; B12-M11Q; B14-H01; D05-H09; A12-V01; A12-W14</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61K-033/02; A61K-033/06; A61K-033/42; A61K-038/00; A61P-035/00; C07K-017/00; A61K-031/66; A61K-047/04; A61K-047/30; A61K-047/42; A61K-009/51</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>WO2018227261-A1&nbsp;</td><td>20&nbsp;Dec&nbsp;2018</td><td>C07K-017/00&nbsp;</td><td>201903&nbsp;</td><td>Pages: 76&nbsp;</td><td>&nbsp;</td>
</tr>
<tr>
<td>BR102017012768-A2&nbsp;</td><td>15&nbsp;Jan&nbsp;2019</td><td>A61K-047/04&nbsp;</td><td>201911&nbsp;</td><td>&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>WO2018227261-A1&nbsp;</td><td>WOBR000031&nbsp;</td><td>14&nbsp;Jun&nbsp;2018</td>
</tr>
<tr>
<td>BR102017012768-A2&nbsp;</td><td>BR10012768&nbsp;</td><td>14&nbsp;Jun&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10012768&nbsp;</td><td>14&nbsp;Jun&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DS </B>
<BR>
</td><td valign="top">WO2018227261-A1:<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
               (National):
               AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
               (Regional):
               BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">99900-1-0-0K P Q; 209582-0-0-0K P Q; 129395-0-0-0K P Q; 99995-0-0-0K P Q; 130323-0-0-0K P Q</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">1787-P; 1801-P</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2018A2140M</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">WO2018227263-A1; BR102017012773-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Obtaining polyvinyl chloride and thermoplastic polyurethane in situ that it is carried out without inertization or solvent use used in in plastified materials, involves mixing polyvinyl chloride, thermal stabilizer and external lubricant</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">DE CARVALHO I M; MEI L H I; RODOLFO A; INNOCENTINI MEI L H; RODOLFO JR. A</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">BRASKEM SA (BRKS-C); UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2018A2140L</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Obtaining polyvinyl chloride and thermoplastic polyurethane in situ that it is carried out without inertization or solvent use involves mixing 50-80 wt.% polyvinyl chloride, preferably 62.5 wt.%, with 0.5 to 3wt.% of thermal stabilizer, preferably 0.62 wt.%, and also with 0.1-1 wt.% of external lubricant , preferably 0.31 wt.%, adding to the product of 0-37.5 wt.% of the plasticizer, preferably 18.6 wt.%; 0.4 to 31wt.% of the polyester diol, preferably 11.5 wt.%; and 0.04 to 3.0 wt.% of the obtained strand extender, preferably 1wt.%;, adding 0.1 to 16.5 wt.% of diisocyanate, preferably 6.08 wt.%, pressing the product for 0.1 to 10 minutes, preferably 5 minutes, at a temperature of 100 to 200 degrees C, preferably 180 degrees C, under a pressure of 2 to 30 mpa, preferably 15 mpa, cooling the product from 0.1 to 10 minutes, preferably 5 minutes, under a pressure of 2 to 30 mpa, preferably 15 mpa, polymerizing the product, calendering, obtaining traction resistant blends.<br>USE - Method for obtaining polyvinyl chloride and thermoplastic polyurethane in situ that it is carried out without inertization or solvent use used in plastified materials.<br>DETAILED DESCRIPTION - The product obtained has Young Modules between 10 mpa and 1467 mpa; with deformation at average rupture between 1% and 350%, preferably 130%; initial thermal degradation (onset) of 245 degrees C to 275 degrees C, preferably 252 degrees C; and with ignition time of 20s to 50s, preferably 27s.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">A14 (Polymers of other substituted monoolefins; including PVC, PTFE.); A25 (Polyurethanes; polyethers.); A32 (Polymer fabrication - such as moulding, extrusion, forming, laminating, spinning.); A97 (Miscellaneous goods not specified elsewhere - including papermaking, gramophone records, detergents, food and oil well applications.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">A04-E02C; A05-G02; A08-A04A; A08-M03; A10-D; A11-A03; A11-B03</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">B29C-043/24; B29K-027/06; C08G-018/12; C08G-018/65; C08G-018/76; C08J-003/18; C08J-003/205; C08L-027/06; C08L-075/04</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>WO2018227263-A1&nbsp;</td><td>20&nbsp;Dec&nbsp;2018</td><td>C08G-018/12&nbsp;</td><td>201902&nbsp;</td><td>Pages: 43&nbsp;</td><td>&nbsp;</td>
</tr>
<tr>
<td>BR102017012773-A2&nbsp;</td><td>15&nbsp;Jan&nbsp;2019</td><td>C08L-027/06&nbsp;</td><td>201911&nbsp;</td><td>&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>WO2018227263-A1&nbsp;</td><td>WOBR050190&nbsp;</td><td>13&nbsp;Jun&nbsp;2018</td>
</tr>
<tr>
<td>BR102017012773-A2&nbsp;</td><td>BR10012773&nbsp;</td><td>14&nbsp;Jun&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10012773&nbsp;</td><td>14&nbsp;Jun&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DS </B>
<BR>
</td><td valign="top">WO2018227263-A1:<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
               (National):
               AE;  AG;  AL;  AM;  AO;  AT;  AU;  AZ;  BA;  BB;  BG;  BH;  BN;  BR;  BW;  BY;  BZ;  CA;  CH;  CL;  CN;  CO;  CR;  CU;  CZ;  DE;  DJ;  DK;  DM;  DO;  DZ;  EC;  EE;  EG;  ES;  FI;  GB;  GD;  GE;  GH;  GM;  GT;  HN;  HR;  HU;  ID;  IL;  IN;  IR;  IS;  JO;  JP;  KE;  KG;  KH;  KN;  KP;  KR;  KW;  KZ;  LA;  LC;  LK;  LR;  LS;  LU;  LY;  MA;  MD;  ME;  MG;  MK;  MN;  MW;  MX;  MY;  MZ;  NA;  NG;  NI;  NO;  NZ;  OM;  PA;  PE;  PG;  PH;  PL;  PT;  QA;  RO;  RS;  RU;  RW;  SA;  SC;  SD;  SE;  SG;  SK;  SL;  SM;  ST;  SV;  SY;  TH;  TJ;  TM;  TN;  TR;  TT;  TZ;  UA;  UG;  US;  UZ;  VC;  VN;  ZA;  ZM;  ZW<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
               (Regional):
               BW;  GH;  GM;  KE;  LR;  LS;  MW;  MZ;  NA;  RW;  SD;  SL;  ST;  SZ;  TZ;  UG;  ZM;  ZW;  EA;  AL;  AT;  BE;  BG;  CH;  CY;  CZ;  DE;  DK;  EE;  ES;  FI;  FR;  GB;  GR;  HR;  HU;  IE;  IS;  IT;  LT;  LU;  LV;  MC;  MK;  MT;  NL;  NO;  PL;  PT;  RO;  RS;  SE;  SI;  SK;  SM;  TR;  OA<BR>
</td>
</tr><tr>
<td valign="top"><B>CP </B>
<BR>
</td><td valign="top">
<table cellspacing="5" cellpadding="1" border="0">
<tr valign="top">
<td valign="top">WO2018227263-A1</td><td nowrap="true">FR2010526-A</td><td>ELASTOMER AG (ELAS)</td><td></td>
</tr>
<tr valign="top">
<td valign="top">&nbsp;</td><td nowrap="true">GB1270836-A</td><td>ELASTOMER AG (ELAS)</td><td></td>
</tr>
<tr valign="top">
<td valign="top">&nbsp;</td><td nowrap="true">US5428087-A</td><td>NORTON CO (NORT)</td><td>PETIT D;  LADANG M</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">621-0-0-0; 444-0-0-0; 238-0-0-0; 19-0-0-0; 1935-0-0-0; 9521-0-0-0; 129431-0-0-0; 2021-0-0-0</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2018A2140L</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017004723-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Method for generating unconventional geometries of subconductor bundles of transmission lines, involves carrying out unconventional geometries optimization and generator process with high transmission capacity</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">DIAS TAVARES M C; ACOSTA SARMIENTO J S</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201895034K</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The method involves obtaining decision variables. Tension level and beam size are determined. Distance is determined between outer and inner phases. Height difference is determined between the outer and inner phases. Height of conductor phases is determined with respect to a ground. Critical electric field of a conductor is determined. Electric field is verified on a surface of the conductor, where electric field is less than or equal to critical electric field. Unconventional geometries optimization and generator process is carried out with high transmission capacity.<br>USE - Method for generating unconventional geometries of subconductor bundles of transmission lines.<br>ADVANTAGE - The method enables carrying out unconventional geometries optimization and generator process so as to improve transmission capacity in an effective manner.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view illustrating a method for generating unconventional geometries of subconductor bundles of transmission lines.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">T01 (Digital Computers); T06 (Process and Machine Control); X12 (Power Distribution/Components/Converters)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">T01-J15B; T01-J15X; T06-A07B; X12-G05</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G05B-017/02; G06F-017/50; H02G-007/20</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017004723-A2&nbsp;</td><td>30&nbsp;Oct&nbsp;2018</td><td>G05B-017/02&nbsp;</td><td>201902&nbsp;</td><td>Pages: 35&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017004723-A2&nbsp;</td><td>BR10004723&nbsp;</td><td>09&nbsp;Mar&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10004723&nbsp;</td><td>09&nbsp;Mar&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201895034K</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102016023207-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Antenna for transmitting and receiving electromagnetic signals in e.g. ultra wide band communication system, has protection module for protecting antenna against atmospheric discharge conditions, where mast structure passes through antenna</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">BASTIDAS J P P; PANICALI A R; DOS REIS E C; PRADO L; NETO J R M; FIGUEROA H E H</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2018979596</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The antenna (A) has a guiding module for guiding electromagnetic energy of an antenna feeding terminal along an azimuthal plane. A protection module (B) is operable for protecting the antenna against atmospheric discharge conditions. A mast structure includes a cross section, where the mast structure longitudinally passes through the antenna and towards an electromagnet energy deficient location to increase electromagnet energy of the electromagnet energy deficient location. An optimization module increases efficiency of protection against atmospheric discharge conditions.<br>USE - Antenna for transmitting and receiving electromagnetic signals in an ultra wide band wireless communication system and an air or land based surveillance system used in war and military services.<br>ADVANTAGE - The protection module provides to the antenna against atmospheric discharge actions. The antenna uses electromagnetic energy, and controls use of electromagnetic spectrum by opponents, thus reducing interference to the user, and improving efficiency of the antenna in robust manner at effective bandwidth rate.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of an antenna integrated with an atmospheric discharge protection module and a tower to support the antenna.<br>Antenna (A)<br>Protection module (B)<br>Radome (C)<br>Tower (D)<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">W02 (Broadcasting, Radio and Line Transmission Systems); W07 (Electrical Military Equipment and Weapons)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">W02-B01C5; W02-B07A1; W02-B08B; W02-B08R1A; W02-B08R1C; W07-X03</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">H01Q-001/50; H01Q-009/28; H01Q-005/25</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102016023207-A2&nbsp;</td><td>21&nbsp;Nov&nbsp;2018</td><td>H01Q-001/50&nbsp;</td><td>201901&nbsp;</td><td>Pages: 32&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102016023207-A2&nbsp;</td><td>BR10023207&nbsp;</td><td>05&nbsp;Oct&nbsp;2016</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10023207&nbsp;</td><td>05&nbsp;Oct&nbsp;2016&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2018979596</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017008497-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Optical fiber i.e. vortex type multimode optical fiber, for use in e.g. spatial division multiplexing network, has covering layer formed for covering distal portion of core adjacent to outer surface of sealing ring arranged in core</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">MILENA SERPA IMBETT C; ZANARELLA M C; FIGUEROA H E H</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201897956W</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The fiber has a core (10) arranged with a sealing ring (20) and surrounded by an intermediate coating element (30), where the intermediate coating element is formed from metamaterial i.e. silica. The core is formed with a solid core structure or filled with air. The sealing ring is placed adjacent to a center portion of the core. A covering layer is formed for covering a distal portion of the core adjacent to an outer surface of the sealing ring. The intermediate coating element comprises a dielectric anisotropic section, which is attached with a substrate part.<br>USE - Optical fiber i.e. vortex type multimode optical fiber (claimed), for use in an optical telecommunications network e.g. spatial division multiplexing (SDM) network and wave division multiplexing (WDM) network, for data transmission applications.<br>ADVANTAGE - The fiber increases number of modes around an angular orbital point so as to enhance orbital angular momentum of the fiber, thus increasing capacity of the telecommunication network, while reducing interference between the modes, and allowing more stable propagation of the modes when the fiber is subjected to external disturbance in simple manner with no need for electronic equalization mechanisms.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a cross-sectional view of a multimode optical fiber.<br>Core (10)<br>Sealing ring (20)<br>Intermediate coating element (30)<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">P81 (Optics (G02).); V07 (Fibre-optics and Light Control); W01 (Telephone and Data Transmission Systems)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">V07-F01A1F; W01-A06C1</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G02B-001/00; G02B-006/02</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017008497-A2&nbsp;</td><td>21&nbsp;Nov&nbsp;2018</td><td>G02B-001/00&nbsp;</td><td>201901&nbsp;</td><td>Pages: 34&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017008497-A2&nbsp;</td><td>BR10008497&nbsp;</td><td>25&nbsp;Apr&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10008497&nbsp;</td><td>25&nbsp;Apr&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201897956W</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017005463-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Method for detection and identification of biomarker for diagnosis of cystic fibrosis, preferably homozygous F508 mutation, involves impregnating molecules in strip, immersing in methanol followed by analyzing sample by mass spectrometry</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">CATHARINO R R; ESTEVES C Z; DE OLIVEIRA D N; DE AGUIAR DIAS L; DE OLIVEIRA LIMA E; RODRIGUES MELO C F; SOUZA GOMEZ C C; RIBEIRO J D; FERNANDO RIBEIRO A; LEVY C E</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2018950332</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - A biomarker (s) detection and identification method involves impregnating molecules in a strip, immersing impregnated strip in 800-1000 ml of 50-80% methanol in a container, adding 0.1-2.0% ammonium hydroxide to the methanol molecule solution followed by placing sample to ionization by electron spray, analyzing the sample by mass spectrometry in negative mode and in the range of 150-700 m/z, and identification of the mass corresponding to the cystic fibrosis biomarker.<br>USE - Method for detection and identification of biomarker(s) for diagnosis of cystic fibrosis, preferably homozygous F508 mutation (all claimed), on the skin.<br>ADVANTAGE - The biomarkers exhibits 90% specificity and 73% sensitivity for diagnosis of cystic fibrosis.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); S03 (Scientific Instrumentation)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B04-N02; B04-N16; B11-C08A; B12-K04G2C; S03-E09F; S03-E10A; S03-E14H</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G01N-033/50; G01N-033/78; G01N-033/88; G01N-033/92</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017005463-A2&nbsp;</td><td>30&nbsp;Oct&nbsp;2018</td><td>G01N-033/50&nbsp;</td><td>201901&nbsp;</td><td>Pages: 24&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017005463-A2&nbsp;</td><td>BR10005463&nbsp;</td><td>17&nbsp;Mar&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10005463&nbsp;</td><td>17&nbsp;Mar&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2018950332</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017007134-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Extruded and expanded morning cereal composition, comprises whole wheat flour, jaboticaba peel flour, and corn flour in which cereal is alternately coated with one or more layers of ingredients contain or not of sugar</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">DE CARVALHO OLIVEIRA L; STEEL C J</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201895029Q</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Extruded and expanded morning cereal composition comprises 80% whole wheat flour, 10% jaboticaba peel flour, and 10% corn flour in which the cereal is alternately coated with one or more layers of ingredients contained or not of sugar.<br>USE - Extruded and expanded morning cereal composition.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">D13 (Other foodstuffs and treatment - including preservation of food, milk, milk products, butter substitutes, edible oils and fats, non-alcoholic beverages, artificial sweeteners, food additives and animal feed (A23B-L).)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">D03-R</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A23L-007/135; A23L-033/22; A23L-007/17</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017007134-A2&nbsp;</td><td>30&nbsp;Oct&nbsp;2018</td><td>A23L-007/135&nbsp;</td><td>201901&nbsp;</td><td>Pages: 51&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017007134-A2&nbsp;</td><td>BR10007134&nbsp;</td><td>06&nbsp;Apr&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10007134&nbsp;</td><td>06&nbsp;Apr&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201895029Q</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR132013032098-E2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Occlusion device for a bronchopleural fistula treatment, comprises five positions allow for adjusting the air flow, where flow sensor of the volumetric capnograph is connected between the orotracheal tube and the ventilator circuit</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">FALCAO A L E; MOREIRA M M; TONELOTO M G C</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201895027J</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The occlusion device comprises five positions allow for adjusting the air flow. A flow sensor of the volumetric capnograph is connected between the orotracheal tube and the ventilator circuit. The alveolar current volume, real time, are checked through the volumetric capnography, while allowing individual therapy. The flow sensor of the allows the measurement of volumetric flow and the percentage of flow.<br>USE - Occlusion device for a bronchopleural fistula treatment.<br>ADVANTAGE - The occlusion device is coupled to the chest drain, regardless of mechanical respirator for reducing the fistula flow, and hence allowing better control of the mechanical breathing, by using of a dynamic adjustment of the flow control. The occlusion device allows different positions for adjusting the air flow.<br>DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for controlling mechanical respiratory lung struck with fistula using the occlusion device.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a graphically represents the behavior of the fistula flow in the multiple treatments using the occlusion device.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">P34 (Sterilising, syringes, electrotherapy (A61L, M, N).); S05 (Electrical Medical Equipment)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">S05-G02E</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61M-016/20</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR132013032098-E2&nbsp;</td><td>30&nbsp;Oct&nbsp;2018</td><td>A61M-016/20&nbsp;</td><td>201901&nbsp;</td><td>Pages: 21&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR132013032098-E2&nbsp;</td><td>BR13032098&nbsp;</td><td>11&nbsp;Dec&nbsp;2013</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR13032098&nbsp;</td><td>11&nbsp;Dec&nbsp;2013&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201895027J</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102016030409-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Method for accepting or rejecting set of population samples from real batch in educational field, involves determining probability of acceptance of batch, evaluating errors of samples, and composing final sample</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">SERGIO MARTINS PEDRO P; URSINI E L</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2018865821</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The method involves selecting to-be-sampled population. To-be-considered parameter is defined in a hypothesis test. Samples are sequentially selected. A parameter measurement process is performed. Mean and standard deviation of the measurements are calculated. Estimated population standard deviation is calculated. Estimated population mean is calculated. Characteristic value of the parameter is calculated under acceptance-reject test. Probability of acceptance of a batch is determined. Errors of the samples are evaluated. The probability of the acceptance is compared with user defined stop criterion. Final sample is composed.<br>USE - Method for accepting or rejecting a set of population samples from a real batch or virtual batch in military and educational fields.<br>ADVANTAGE - The method enables minimizing costs/risks of sampling by maintaining quality requirements, and accepting or rejecting the set of the samples from the real batch in a flexible manner.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">T01 (Digital Computers)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">T01-J03; T01-J04D; T01-J30A</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G06F-017/18</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102016030409-A2&nbsp;</td><td>14&nbsp;Aug&nbsp;2018</td><td>G06F-017/18&nbsp;</td><td>201901&nbsp;</td><td>Pages: 32&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102016030409-A2&nbsp;</td><td>BR10030409&nbsp;</td><td>21&nbsp;Dec&nbsp;2016</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10030409&nbsp;</td><td>21&nbsp;Dec&nbsp;2016&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2018865821</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102017006606-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Electro-optical space switch i.e. semiconductor optical amplifier, for amplifying optical carrier for transmission of information in telecommunication systems, has gold plate for transmitting signals to optical amplifier anode</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">CONFORTI E; CARVALHO FIGUEIREDO R; SUTILI T; DOS SANTOS RIBEIRO N; DE MELLO GALLEP C</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C); PADTEC SA (PADT-Non-standard)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201895030V</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The switch has a transmission line section for input of microwave signal, and arranged in a thin gold film. The thin gold film is firmly attached to a gold plate (13) by a metal braid (12), which is coated with gold. The gold plate transmits signals to a semiconductor optical amplifier (SOA) anode (5) and a SOA (6). A ground plane comprises a screw-type metal connector, which connects an integrated photonic structure to a Peltier element for controlling temperature of the switch. The ground plane is optionally placed in the integrated photonic structure, which contains the SOA and a thin film resistor (1). An alumina plate (10) is optionally replaced with insulating material such as yttrium and iron grenade, gallium arsenide and indium phosphide.<br>USE - Electro-optical space switch i.e. SOA, for amplifying an optical carrier for transmission of information in telecommunication systems.<br>ADVANTAGE - The switch ensures stabilization of fundamental parameters and reaches high integration degree, and has low energy expenditure.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a schematic partial sectional view of electrical and optical components of an electro-optical space switch. '(Drawing includes non-English language text)'<br>Thin film resistor (1)<br>Anode (5)<br>Semiconductor optical amplifier (6)<br>Alumina plate (10)<br>Metal braid (12)<br>Gold plate (13)<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">P81 (Optics (G02).); V07 (Fibre-optics and Light Control)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">V07-K01C1</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G02B-006/30; G02B-006/122</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102017006606-A2&nbsp;</td><td>30&nbsp;Oct&nbsp;2018</td><td>G02B-006/30&nbsp;</td><td>201882&nbsp;</td><td>Pages: 42&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102017006606-A2&nbsp;</td><td>BR10006606&nbsp;</td><td>28&nbsp;Mar&nbsp;2017</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10006606&nbsp;</td><td>28&nbsp;Mar&nbsp;2017&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201895030V</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102016031052-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Quartz tube component for photocatalytic reactor, has transverse bands with catalytic coating alternating with uncoated bands, where the catalytic coating comprises photocatalyst, and the photocatalyst is preferably titanium dioxide</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">DOUBEK U L R; TOMAZ E</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201895038S</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Quartz tube component has transverse bands with catalytic coating alternating with uncoated bands at the rate of recoating variable from 65-70% of the sum of the areas of the covered and uncoated bands.<br>USE - Quartz tube component for photocatalytic reactor.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">J04-E04C</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">B01J-019/12; B01D-053/88</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102016031052-A2&nbsp;</td><td>30&nbsp;Oct&nbsp;2018</td><td>B01J-019/12&nbsp;</td><td>201882&nbsp;</td><td>Pages: 27&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102016031052-A2&nbsp;</td><td>BR10031052&nbsp;</td><td>22&nbsp;Dec&nbsp;2016</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10031052&nbsp;</td><td>22&nbsp;Dec&nbsp;2016&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201895038S</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102016021317-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Transdermal composition used in preparing medicament for treating malaria caused by Plasmodium falciparum, comprises artemether drug associated with one or more pharmaceutical components in form consisting of embossing agent</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">ZANUTTO F V; SANTOS B F; COSTA SALLES T H; DE DEUS MORAES SEGUNDO J; D AVILA M A; DE OLIVEIRA SOUSA I M; SERVAT-MEDINA L; CHORILLI M; FOGLIO M A</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C); UNIV ESTADUAL PAULISTA JULIO MESQUITA (UYES-Non-standard)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2018906952</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Transdermal composition comprises artemether drug associated with one or more active pharmaceutical components in form consisting of embossing agent, crystalline liquid system, membrane of electrospinning or at least association of two of same.<br>USE - Transdermal composition used in preparing medicament for treating malaria caused by Plasmodium falciparum (claimed).<br>ADVANTAGE - The transdermal composition enables to avoid the first-pass metabolism that occurs after the systemic oral administration, and it is an alternative to drugs that cannot be absorbed from the digestive tract.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B07 (General - tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.); B05 (Other organics - aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 - B05.); A96 (Medical, dental, veterinary, cosmetic.)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B04-B01C3; B04-C02A2; B04-C02E3; B04-C03; B04-N02; B08-D03; B10-A07B; B10-B01B; B10-C04D; B10-D03; B10-E02; B10-E04C; B10-E04D; B12-M02F; B12-M10; B12-M11H2; B14-A03B; A10-E07B; A10-E08A; A10-E08B; A10-E09; A11-B02; A11-B15; A12-S05L; A12-V01</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61K-009/70; A61K-031/357; A61K-031/137; A61K-047/38; A61P-033/06</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102016021317-A2&nbsp;</td><td>18&nbsp;Sep&nbsp;2018</td><td>A61K-009/70&nbsp;</td><td>201882&nbsp;</td><td>Pages: 29&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102016021317-A2&nbsp;</td><td>BR10021317&nbsp;</td><td>15&nbsp;Sep&nbsp;2016</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10021317&nbsp;</td><td>15&nbsp;Sep&nbsp;2016&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">3330-0-0-0K M; 101244-0-0-0K M; 102701-2-0-0K M; 104851-0-0-0K M; 107456-1-0-0K M; 5735-0-0-0K M; 125057-0-0-0K M; 7275-0-0-0K M; 7447-0-0-0K M; 490-0-0-0K M; 7584-0-0-0K M; 861-0-0-0K M; 87792-1-0-0K M; 91481-0-0-0K M; 91821-0-0-0K M; 95972-0-0-0K M; 97261-0-0-0K M; 97485-1-0-0K M; 97486-1-0-0K M; 103242-0-0-0K M; 104328-1-0-0K M; 104479-0-0-0K M; 104488-0-0-0K M; 131343-0-0-0K M; 135411-0-0-0K M; 1062-0-0-0K M; 829-0-0-0; 7560-0-0-0; 133920-0-0-0; 135340-0-0-0; 133996-0-0-0; 444-0-0-0; 238-0-0-0</td>
</tr><tr>
<td valign="top"><B>RI</B></td><td valign="top">66132</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>RG </B></td><td valign="top">0195-S; 0954-S; 0607-S; 0032-S; 0758-S; 0689-S; 0009-S; 0113-S; 2069-S; 0137-S; 1859-S; 1870-S</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2018906952</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102015021672-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Detecting and identifying specific lipid biomarker for leprosy involves impregnating molecules on an imprinting strip, immersing sorbent impregnated in methanol in suitable container, adding formic acid to the solution of methanol-molecules</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">CATHARINO R R; DE OLIVEIRA LIMA E; ESTEVES C Z; DE OLIVEIRA D N; SANTOS DE MACEDO C; DA COSTA NERY J A; PESSOLANI M C V; SARNO E N</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">2018888336</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Detecting and identifying specific lipid biomarker for leprosy involves impregnating the molecules on an imprinting strip, immersing sorbent impregnated in 0.5 to 2 mL of 50 to 100% methanol in a suitable container, adding formic acid in a concentration ranging from 0.1-1.0% to the solution of methanol-molecules, submitting sample to ionization by electron spray, analyzing sample by mass spectrometry (ESI-MS), identifying mass/load corresponding to the specific biomarker (s) of interest and verifying presence or absence of specific lipid biomarker (s) specific for leprosy.<br>USE - Method for detecting and identifying specific lipid biomarker for leprosy.<br>ADVANTAGE - The method enables to detect and identify specific lipid biomarker for leprosy in easy, quick and painless way.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.); B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); D16 (Fermentation industry - including fermentation equipment, brewing, yeast production, production of pharmaceuticals and other chemicals by fermentation, microbiology, production of vaccines and antibodies, cell and tissue culture and genetic engineering.); J04 (Chemical/physical processes/apparatus - including catalysis, catalysts (excluding specific e.g. enzymatic or polymerisation catalysts), colloid chemistry, laboratory apparatus and methods, testing, controlling, general encapsulation, detection and sampling (excluding clinical testing) (B01J, L).); S03 (Scientific Instrumentation)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">A12-E13; A12-V03C2; B04-B01B; B11-C08A; B11-C11; B12-K04G1C; D05-H09; J04-B01A1; J04-C01; J04-C02; S03-E09F; S03-E14H</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G01N-033/92; G01N-033/569</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102015021672-A2&nbsp;</td><td>18&nbsp;Sep&nbsp;2018</td><td>G01N-033/92&nbsp;</td><td>201881&nbsp;</td><td>Pages: 22&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102015021672-A2&nbsp;</td><td>BR10021672&nbsp;</td><td>04&nbsp;Sep&nbsp;2015</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10021672&nbsp;</td><td>04&nbsp;Sep&nbsp;2015&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:2018888336</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR200703005-B1</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Method for determining a release profile of encapsulated products, involves mixing a medium and encapsulated product in a cuvette before separation of the solid phase in a liquidizer system from the liquid phase in a release medium</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">ATILIO JORGE R; ROMERO DA SILVA A</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201888819M</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The method involves mixing a medium and encapsulated product in a cuvette (4) before separation of the solid phase in a liquidizer system from the liquid phase in a release medium. The cuvette is positioned in front of an insertion slot (5) of an integrating ball (3) of a diffuse diffusion accessory (2), which is coupled to a spectrophotometer (1). A solid pattern is constituted by a substance having a high reflectance, is positioned in a recess (6) of the integrating ball of the diffuse diffusion accessory. An absorption spectra of the released product is obtained. The encapsulated product is provided with a carrier system. The absorption spectra is obtained until the absorbance intensity detected in the spectra is stabilized. A quantification of the total mass of product is released after stabilization of the absorbance intensity.<br>USE - Method for determining a release profile of encapsulated products, particularly encapsulated drugs, such as mesotetraphenylporphyrin encapsulated in nanoparticles of the lactic acid or glycolic acid copolymer.<br>ADVANTAGE - Precise determination of the release profile of the encapsulated drug is performed without generating waste.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a perspective view of a spectrophotometer.<br>Spectrophotometer (1)<br>Diffuse diffusion accessory (2)<br>Integrating ball (3)<br>Cuvette (4)<br>Insertion slot (5)<br>Recess (6)<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">B04 (Natural products and polymers. Including testing of body fluids (other than blood typing or cell counting), pharmaceuticals or veterinary compounds of unknown structure, testing of microorganisms for pathogenicity, testing of chemicals for mutagenicity or human toxicity and fermentative production of DNA or RNA. General compositions.); A89 (Photographic, laboratory equipment, optical - including electrophotographic, thermographic uses.); S03 (Scientific Instrumentation)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">B11-C07B2; B12-K04E; A05-E02B; A09-B; A12-E13; A12-W05; A12-W14; S03-E04B; S03-E04C</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">G01N-021/47</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR200703005-B1&nbsp;</td><td>21&nbsp;Aug&nbsp;2018</td><td>G01N-021/47&nbsp;</td><td>201881&nbsp;</td><td>Pages: 15&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR200703005-B1&nbsp;</td><td>BR003005&nbsp;</td><td>18&nbsp;Jul&nbsp;2007</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR003005&nbsp;</td><td>18&nbsp;Jul&nbsp;2007&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">7560-0-0-0; 7447-0-0-0</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201888819M</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR202016016366-U2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Dental device comprises a directional buttons that are provided with the control unit, such that the central button is provided to control the functions of power on and off of the display, and body that is equipped with a display</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">CARVALHO RAMOS SALLES DE; ROCHA M G; COELHO SINHORETI M A; BORTOLAZZO CORRER A; CANGIANI M B</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201888838W</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - The dental device comprises a body (1) that is equipped with a display (2). A control unit (3) is equipped with an emission point, and a light emitting diode is equipped with the body. The display is provided with the plastic material, such that the rounded surfaces are provided. The directional buttons are provided with the control unit, such that the central button controls the functions of power on and off of the display, while actuating the light to control the functions of navigation and control adjustments of the display.<br>USE - Dental device.<br>ADVANTAGE - Ensures efficient usage of the dental device, such that it ensures the reliability and durability of the dental device.<br>DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of a dental device.<br>Body (1)<br>Display (2)<br>Control unit (3)<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">A96 (Medical, dental, veterinary, cosmetic.); P31 (Diagnosis, surgery (A61B).); U12 (Discrete Devices)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">A12-V03C1; A12-V03C2; U12-A01A7</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">A61B-005/00</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR202016016366-U2&nbsp;</td><td>14&nbsp;Aug&nbsp;2018</td><td>A61B-005/00&nbsp;</td><td>201881&nbsp;</td><td>Pages: 13&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR202016016366-U2&nbsp;</td><td>BR20016366&nbsp;</td><td>14&nbsp;Jul&nbsp;2016</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR20016366&nbsp;</td><td>14&nbsp;Jul&nbsp;2016&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201888838W</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr><tr>
<td valign="top"><B>PT </B></td><td valign="top">P</td>
</tr><tr>
<td valign="top"><B>PN </B></td><td valign="top">BR102016020042-A2</td>
</tr><tr>
<td valign="top"><B>TI </B></td><td valign="top">Photopolymerizable resinous composite used in direct dental restorative materials, comprises particles and resin based matrix comprising dimethacrylate demonomers, methacrylate monomerisorbonyl, and photoinitiator system</td>
</tr><tr>
<td valign="top"><B>AU </B></td><td valign="top">FAVARAO J; MENDONCA M J; FLORE G A; ZANINI M M; ROCHA M G; CARVALHO RAMOS SALLES DE; COELHO SINHORETI M A</td>
</tr><tr>
<td valign="top"><B>AE </B></td><td valign="top">UNICAMP UNIV ESTADUAL CAMPINAS (UNES-C); UNIV ESTADUAL DO OESTE DO PARANA (UYES-Non-standard)</td>
</tr><tr>
<td valign="top"><B>GA </B></td><td valign="top">201886582D</td>
</tr><tr>
<td valign="top"><B>AB </B></td><td valign="top">NOVELTY - Photopolymerizable resinous composite comprises 60 to 90 wt.% particles, 10-40 wt.% resin based matrix comprising 59.4 to 79.8 wt.% dimethacrylate demonomers, 19.8 to 39.8 wt. % methacrylate monomerisorbonyl, and 0.4 to 0.8 wt.% photoinitiator system.<br>USE - Photopolymerizable resinous composite used in direct dental restorative materials.<br>
</td>
</tr><tr>
<td valign="top"><B>DC </B></td><td valign="top">A96 (Medical, dental, veterinary, cosmetic.); A14 (Polymers of other substituted monoolefins; including PVC, PTFE.); A25 (Polyurethanes; polyethers.); D21 (Preparations for dental or toilet purposes - including filling alloys, compositions for dentures or dental impressions, anti-caries chewing gum, plaque disclosing compositions, toothpastes, cosmetics, shampoos, topical anti-sunburn compositions and toilet soaps (A61K).)</td>
</tr><tr>
<td valign="top"><B>MC </B></td><td valign="top">A02-A09; A04-B09; A04-F06E5; A12-V02B; D08-A02</td>
</tr><tr>
<td valign="top"><B>IP </B></td><td valign="top">C08L-033/10; C08K-003/013; A61K-006/00; A61K-006/02; C08L-023/26</td>
</tr><tr>
<td valign="top"><B>PD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr style="font-weight: bold; color: #666666; background-color: #E3EEFB ;">
<td valign="center" align="left">
                        Patent Number
                   </td><td valign="center" align="left">
                        Publ. Date
                   </td><td valign="center" align="left">
                        Main IPC
                   </td><td valign="center" align="left">
                        Week
                   </td><td valign="center" align="left">
                        Page Count
                   </td><td valign="center" align="left">
                        Language
                   </td>
</tr>
<tr>
<td>BR102016020042-A2&nbsp;</td><td>14&nbsp;Aug&nbsp;2018</td><td>C08L-033/10&nbsp;</td><td>201880&nbsp;</td><td>Pages: 13&nbsp;</td><td>English&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>AD </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR102016020042-A2&nbsp;</td><td>BR10020042&nbsp;</td><td>30&nbsp;Aug&nbsp;2016</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>PI </B>
<BR>
</td><td valign="top">
<table bordercolor="#CCCCCC" cellpadding="3" cellspacing="0" border="1">
<tr>
<td>BR10020042&nbsp;</td><td>30&nbsp;Aug&nbsp;2016&nbsp;</td>
</tr>
</table>
<BR>
</td>
</tr><tr>
<td valign="top"><B>DN </B></td><td valign="top">192001-0-0-0; 129676-0-0-0; 11968-2-0-0; 444-0-0-0</td>
</tr><tr>
<td valign="top"><B>CI </B></td><td valign="top">RA0149K M; RA0CPWK M; R01693K M; R00113K M; R01163K M; R00990K M; R14121K M; R01514K M; R01833K M; RA00JWK M; R01869K M; RA0135K M; R00351; R00370; RACGGCK S; RABL2QK S; R01391K U V; R01706K U V; R01744K U V; R01704K U V; R01066K U V; R01697K U V; R01973K U V; R01534K U V; R01513K U V; R03031C K; R01669C K; R05085C K; RA00HSC K; RCIR9XK P; RCIR9YK P; R00611K M; R03812K M; R07226; R03882; R03275; R01863; R24037; RA086PK M; R00363; R24078; R01852; R05319; RA0E6SK P Q; RA0JR4K P Q; RAC6VAK P Q; R01787K P Q; R01801K P Q; RBZ0WTK P Q; R00338; R00895; R00908; R00735; R00982; R00122; R00195K M; R12505K M; RAHT0ZK M; R00954K M; R00607K M; R00032K M; R00758K M; R22613K M; R00689K M; R00009K M; R02069K M; R00137K M; RA08CAK M; R24034K M; RA002WK M; R24033K M; R01859K M; RA016GK M; R03005K M; RA083KK M; RA0218K M; R01870K M; RA04WZK M; R08416K M; R24068K M; RA00D5K M; R00835; R00448; R06563; R24016; R05378; R03348</td>
</tr><tr>
<td valign="top"><B>UT </B></td><td valign="top">
       DIIDW:201886582D</td>
</tr><tr>
<td><B>ER</B></td><td></td>
</tr><tr>
<td colspan="2">
<hr>
</td>
</tr>
<tr><td>EF</td><td></td></tr></table>
